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ABSTRACT 
 
Genetically engineered animal models of diseases are increasingly recapitulating 
human diseases.  With this, in vivo preclinical imaging of small laboratory animals has 
emerged as a critical component of biomedical research because of its noninvasive 
nature allowing serial assay of animal models and monitoring its safety and effectiveness 
over the history of the disease. The concept of quantitative molecular imaging is to go 
beyond displaying images in digital form and to consider the image and extract 
quantitative information that allows for a better understanding of disease progression and 
treatment.  The aim of this work is to demonstrate the need for the metrology of 
molecular imaging of animal models using micro-PET/CT devices.  
System characteristics are determined within each subsystem, micro-PET and 
micro-CT, independent of each other, and as integrated systems. The characterization of 
tissues, composition and density, by micro-CT was determined along with the noise 
level of the unit. Moreover, the nominal superficial and deep absorbed doses were 
estimated to assess the confounding effect of multiple scans in animal studies. The Q 
value, used to convert counts per milliliter to activity per milliliter, was estimated to 
assess the observed activity present in the animal. The resolution of the micro-PET 
subsystem was also estimated using a modified Derenzo phantom to assess the 
uncertainty of the activity distribution within tissues. Once both modalities were 
characterized separately the coordinate system of each individual system was checked 
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for spatial accuracy using a cross capillary method. The offset values were then used to 
establish the same coordinate system for co-registration.  
 Once both micro-PET and micro-CT image data sets had been verified, they were 
used to generate a voxel image of the subject for use in the Monte Carlo program, 
MCNP6, where an absorbed dose map was generated for the radiolabeled compound. 
Two basic examples are given to demonstrate the use of the voxelized absorbed dose 
maps for calculating the absorbed dose to any segmented organ of interest, across 
longitudinal studies. In this way, it was shown that an animal-specific model can be used 
to accurately calculate the absorbed dose for each time point during a study. 
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1 INTRODUCTION 
 
Molecular imaging can be defined as the in vivo visualization, characterization 
and spatiotemporal quantitative measurement and distribution of biological processes at 
the molecular and cellular levels, associated with a biochemical, biological, diagnostic, 
or therapeutic application. During the last three decades, the field of molecular imaging 
has grown exponentially, and it is now academically listed as an integral part of the 
biomedical sciences along with genomics, proteomics, and metabolomics.  
As part of molecular imaging, radiological imaging has long been an 
indispensable tool in clinical medicine. In clinical practice, a significant effort has been 
placed in establishing protocols and standards in 2D and 3D image metrology in 
radiology, radiotherapy and nuclear medicine; however, at the preclinical level, little 
effort has been placed to establish such standards and protocols.  
In vivo imaging of small laboratory animals has emerged as a critical component 
of preclinical biomedical research. Small-animal imaging provides a noninvasive means 
of assaying biological structure and function in vivo, yielding qualitative and 
quantitative, spatiotemporal information on normal and diseased tissues, such as tumors. 
Because of its noninvasive nature, imaging allows serial (i.e. longitudinal) assay of 
animal models, such as rodents, over the entire natural history of the disease process, 
from inception to progression, and monitoring of the effectiveness of treatment strategies 
or other interventions (with each animal serving as its own control and thereby reducing 
biological variability). This also serves to minimize the number of experimental animals 
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required for a study. With the ongoing development of genetically engineered (i.e., 
transgenic and knockout) rodent models of cancer and other critical diseases, such 
models are increasingly more realistic in recapitulating the sequelae of the corresponding 
human disease and the ability to track these disease models long-term is therefore 
invaluable. Importantly, in contrast to cell or tissue culture-based experiments, studies in 
intact animals incorporate interacting physiological factors –neuronal, hormonal, 
nutritional, immunological, etc. – present in the complex in vivo milieu. Therefore, the 
concept of quantitative molecular imaging is to go beyond displaying images in digital 
form and to consider the image and extract quantitative information that will allow for a 
better understanding of a disease.  
 Preclinical molecular imaging requires that imaging data are quantitatively 
representative of the physical and physiological properties and processes being observed 
in animal models. This will allow the creation of metadata for quantitative imaging 
informatics and image markup. In the case of micro-PET/CT, there are two specific 
imaging modalities that require quantitation and integration. These are micro-CT and 
micro-PET; where each modality requires specific standardization protocols that will 
ensure the quantitative quality of the data for integration with each other and other non-
imaging modalities.   
 This dissertation aims to demonstrate the need for standardization and 
quantification of micro-PET/CT devices at the preclinical level. Optimal methods are 
proposed for both PET and CT units along with their integration of the data sets. Once 
standardization is established, acquired images are used to generate a voxel image of the 
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subject in a Monte Carlo program where a dose map is generated for any specific source, 
or radiolabeled compound. In this way, a patient specific model is used to more 
accurately generate the dose to each individual subject and the dose to any region can be 
easily extracted using segmentation. 
 
1.1 The Relevance of Radiation Metrology in Molecular Imaging and Radiotherapy 
 Despite large investments in drug development, the overall success rate of drugs 
remains very low. This high attrition rate is mostly due to a lack of a validated 
translational continuum yielding unsound and unstructured preclinical research. 
According to the Pharmaceutical Research and Manufacturers of America, in 2015 there 
were more than 830 drugs and vaccines being developed for cancer therapy and other 
diseases. Based on the current attrition rate, many of these drugs will fail during 
preclinical studies or Phase I/II clinical trials. Furthermore, many approved drugs are 
withdrawn after unforeseen adverse drug reactions during post-market surveillance, 
increasing the overall cost of drug development. It has been asked, “Can we do better?”. 
The answer is yes; however, there is a need to raise the standards for preclinical research 
by improving the preclinical research environment. Therefore, animal models of diseases 
with higher disease fidelity and reproducibility are needed. When adequately conceived, 
animal models can contribute invaluable information to our knowledge of biology and 
medicine, including the discovery and development of new drugs. High fidelity animal 
models of diseases can help establish specific biomarkers associated with biological 
pathways that can help in the diagnosis of diseases and development of drugs. However, 
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biomarker qualification and drug development, as per US FDA guidelines, is riddled 
with regulatory processes that can only be addressed through well-conceived and 
executed preclinical animal studies. The characterization, validation of animal models, 
and their use in biomedical studies requires non-invasive imaging infrastructure where 
they can quantitatively be observed and analyzed.  
 
1.1.1 Clinical Efforts   
 As mentioned above, protocols and standards are not well established at the pre-
clinical level. In the United States, the National Institute of Standards and Technology 
(NIST), Radiation Physics Division, in collaboration with the Quantitative Imaging 
Network of the Cancer Imaging Program at the National Cancer Institute, are carrying 
out research efforts in establishing the necessary methods and algorithms for the 
quantitation of images, such as radiological (planer x-ray, CT, MRI), molecular imaging 
(planar, SPECT, PET), or hybrid imaging modalities [1-6]. In Europe, the National 
Physical Laboratory of the UK, established the Molecular Radiotherapy Dosimetry 
(MRT Dosimetry) Project, which has been working on establishing standards for 
molecular imaging and molecular radiotherapy under the sponsorship of the “European 
Metrology Programme for Innovation and Research” (EMPIR) [7, 8].  
Significant efforts have been made in quantitative image and lesion segmentation 
of tumors [9], establishment of basic requirements for institutions carrying out clinical 
trials using PET/CT imaging [10], and assessment of early response to oncology 
therapies using FDG-PET/CT [11]. A full description of the quantitative imaging efforts 
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from multiple groups within the Quantitative Imaging Network are presented in the 
following references [1-6].  
 
1.1.2 Preclinical Efforts 
 To expedite the study of biological phenomena, disease etiology, diagnosis and 
therapy, new observational modalities using in vivo animal models are needed. Small 
animal models, particularly genetically engineered mice, are increasingly recognized as 
powerful discovery tools in biomedical research. The number of animal models of 
human diseases has increased exponentially, with an associated dramatic increase in an 
understanding of their spatiotemporal pathophysiology. In 1998, the US National 
Institutes of Health (NIH) established the Small Animal Imaging Resource Program 
(RFA-CA-98-023) to develop and enhance (a) shared imaging research resources to be 
used by investigators, (b) research related to small animal imaging technology, and (c) 
training the next generation of professional and technical personnel interested in the 
science, techniques and use of small animal and molecular imaging. This has led to an 
extraordinary increase in biomedical research and publications related to small animal 
imaging and translational research, including nanotechnology-based applications. Major 
research universities have responded aggressively to this initiative with an associated 
increase in publications and funding. Small animal molecular imaging has a significant 
role in drug discovery and development.  
 Today, most major research institutions across the world have a small animal 
imaging core facility, which has led to the establishment of molecular imaging programs 
as a preclinical research area. Molecular imaging provides whole-body phenotyping in 
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an intact animal, which is more relevant than time consuming in vitro/ex vivo animal 
studies. Molecular imaging decreases the workload and accelerates biomedical research, 
by providing statistically accurate results through longitudinal studies, which can be 
performed in the same living subject. This has led to a surge in the development and 
study of molecular imaging probes and contrast agents using novel compounds and 
nanotechnology-based strategies. As a consequence, the NIH established the Molecular 
Imaging and Contrast Database (MICAD) to classify the more than 4,250 probes that 
have been developed by major imaging modality (i.e., PET, SPECT, MRI, optical, etc.) 
and targeting mechanisms. Furthermore, these core facilities have helped the 
development of nanotechnology-based strategies, which further led to the establishment 
of the NCI Nanotechnology Characterization Laboratory (https://ncl.cancer.gov) that is 
dedicated to assessing the immunotoxicity and overall safety and efficacy of 
nanotechnology-formulated drugs and nanoparticles used in cancer diagnosis, 
theranostics and therapy [12-20]. 
 Molecular imaging provides continuity for the in vivo evaluation of animal 
models of diseases, safety and efficacy drugs. Small animal models of disease can help 
evaluate the physiological and metabolic effects and cytotoxic response to drugs, 
including radiotherapy, chemotherapy, and immunotherapy agents to those in humans. 
This translational stage, in turn, may help reduce the high attrition rates for novel cancer 
diagnostic and therapeutic drugs. 
 An effort has been placed in characterizing many preclinical molecular imaging 
devices, such as micro-PET/CT; however, the characterization does not include the 
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specific radionuclides in combination with animal models. For example, a conversion 
factor can be determined to convert machine counts into an activity concentration for 
NaF in a water phantom but when injected into a subject, this compound will seek out 
and attach to bone surfaces. With bone on one side of the compound and tissue on the 
other, the attenuation values and coincidence counts will be different than those 
measured in the pure water phantom causing a misrepresentation of the total activity 
present. New standards and methods need to be developed to incorporate the quantitative 
values of the micro-PET/CT associated with the subject being studied.  
 
1.2 Animal Models of Diseases 
 Animal models of human diseases are a fundamental pillar in preclinical studies. 
They have helped characterize the pathophysiology of many diseases, allowing us to 
understand their etiology, molecular pathways, mechanism of action, and study the 
safety and efficacy of drugs. However, there has been significant and valid criticism 
regarding their use; this criticism has been substantiated by using animal models that 
lack disease fidelity, reproducibility of research findings, and failure in predicting or 
correlating with human clinical trials. It has been asserted that researchers are culpable 
of wasting time, money, animal resources, and, therefore, slowing the scientific progress 
by presenting non-reproducible data, and thus misinforming other researchers and the 
public at large. A succinct review of the current ethical issues in animal experimentation 
is given in Akhtar [21]. These criticisms have led to the establishment of collaborative 
groups, such as CAMARADES (Collaborative Approach to Meta-Analysis and Review 
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of Animal Data from Experimental Studies), which carries systemic reviews and meta-
analysis from experimental animal models. The group advocates for the use of high 
fidelity animal models and randomization in preclinical trials to ensure reproducibility 
and reduce bias. Moreover, the group showed in a systemic review of preclinical animal 
studies that few well-defined and conceived studies are predictive of clinical efficacy in 
human clinical trials. These criticisms have led many high-impact scientific journals to 
demand substantial statistical proof of research findings by means of longitudinal 
preclinical studies, and well-established biological endpoints by means of non-invasive 
quantitative in vivo molecular imaging. 
 In general, experimentation with animal models falls under two categories. These 
are 1) basic experimentation, which is directed at investigations in basic biology and 
human disease, and 2) applied experimentation, which is directed at investigating drug 
research and development, and toxicity and safety testing. Regardless of the focus, 
animal experimentation is intended to inform human biology and health sciences and to 
promote the safety and efficacy of potential treatments. There is a plethora of animal 
models of diseases, and each animal model is amenable for some type of molecular 
imaging [22-40]. There are pertinent animal models of diseases, including 
immunological, neurological, mental disorders [41], models of cancer and cancer 
prevention [42, 43]. Animal models are divided into three convenient groups. These are 
1) experimentally induced animal models, 2) spontaneous animal models, and 3) 
genetically engineered animal models using CRISPR/Cas-9 gene editing [44-46].  
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1.3 Molecular Imaging Probes 
 A fundamental area of molecular imaging is the development of molecular 
probes to assess the pathophysiology of disease and disease response to therapies. 
Molecular imaging probes help scientists better understand cellular processes and how 
therapeutic drugs modulate those processes or pathways in a relevant biological context. 
The basic composition of a molecular imaging probe is based on a signaling agent 
attached to a specific targeting moiety using a linker. Signaling agents can be based on 
PET, SPECT, optical, MR, or multimodality agents, and targeting moieties can be 
viruses, small molecules, peptides, large proteins, antibodies, and even nanoparticles. 
There are other switch-and-click combinations for developing probes. Molecular probes 
need to be selected based on their relationship with disease pathophysiology. Many 
probes are being developed by searching small molecular libraries for a hit compound 
against a specific target with high affinity. High through-put screening (HTS) is a 
widely-utilized technology for drug discovery. The establishment of these molecular 
libraries is by itself a whole research paradigm in medicinal chemistry where molecular 
imaging plays an important role. Once a target has been validated, HTS is used to search 
for leading compound candidates. Selected compounds can then be modified by 
constructing homology models that are amenable for imaging or for the generation of 
potential drugs.  
 There is a plethora of molecular imaging probes. In oncology, the primary 
molecular probe continues to be [18F]FDG-PET/CT; however, there are activity-based 
molecular probes tagged with other PET radionuclides to visualize programmed cell 
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death (apoptosis via caspases), inflammation, or for in vivo monitoring of EGFR, HER2 
or VEGF expression. In cardiology, hybrid [18F]FDG-PET/CT is used as a biomarker for 
the detection of inflammatory cardiomyopathies, and cardiac sarcoidosis. In 
neurodegenerative diseases, [18F]TSPO-PET/CT has been used to assess brain ischemia 
and high-grade glioma, and neuro-inflammation due to Alzheimer's and Parkinson’s 
disease. 
 Another emerging area in molecular imaging is the assessment of microbial 
based cancer therapies. The use of bacteria in the regression of certain forms of cancer 
has been recognized for more than a century. There were many anecdotal studies in the 
past but now it has been shown that commensal bacterial induces homeostasis, which 
can prevent cancer induction, progression and regression. Bacteria can also be used as 
vectors by loading them with natural products such as therapeutics, which is an 
appealing strategy.  
 
1.4 Quantitative Imaging Biomarkers (QIB) 
 Detecting a disease, including cancer, at an early stage is one of the most 
important issues for increasing the recovery and survival rate of patients. Cancer 
biomarker detection helps to provide a diagnosis before the disease becomes incurable in 
later stages. Molecularly targeted cancer drugs are often developed with companion 
diagnostics that attempt to identify which patients will have a better outcome on the new 
drug than the control regimen. Such predictive biomarkers are playing an increasingly 
important role in precision medicine. For diagnostic tests, sensitivity, specificity, 
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positive predictive value (PPV), and negative predictive value (NPV) are usually used as 
performance measures. For the case of imaging predictive biomarkers, they also need to 
be characterized for their specificity, sensitivity, PPV, and NPV [47].  Examples of 
imaging biomarkers are those associated with cognitive decline, such as Alzheimer’s 
disease.  
 In drug discovery and development, biomarkers play a crucial role in 
understanding the mechanism of action of a drug, identifying efficacy or toxicity signals 
at an early stage of development and in identifying patients likely to respond to a 
specific treatment. The biomarker definitions working group of the NIH established the 
following definition of a biomarker. 
 
 Biological marker (biomarker): A characteristic that is objectively measured and 
 evaluated as an indicator of normal biological processes, pathogenic processes, 
 or pharmacologic responses to a therapeutic intervention [48].  
 
 The term ‘biomarker’ covers a very wide range of data types, uses and 
applications across all stages of pharmaceutical development. Biomarkers are 
categorized into the following 1) Prognostic biomarker: Predicts the likely disease 
prognosis independent of the mode of treatment, 2) Predictive biomarker: Predicts the 
likelihood of response to a treatment or class of treatments, and 3) Pharmacodynamic 
biomarker: Responds overtime to a treatment intervention. 
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 Biomarkers can further be divided depending on the mode of data collection [49]. 
Three types of biomarkers can be recognized 1) Biochemical or histological parameters 
detected on tissue samples obtained from biopsy or surgery samples, 2) Biochemical 
parameters or cells obtained on blood or urine samples, and 3) Anatomical, functional or 
molecular parameters detected with imaging.  
 In a recent article, the Quantitative Imaging Biomarkers Alliance Working Group 
(QIBA) of the Radiological Society of North America (RSNA) described the relevant 
metrological concepts and methods needed for evaluating and comparing QIBs, and 
discussed the issues associated with the technical performance related to imaging 
biomarkers [50, 51].  
 Development of imaging biomarkers is an organized process in which new 
biomarkers are discovered, verified, validated and qualified against biological processes 
and clinical end-points [52]. The validation process not only concerns the determination 
of the sensitivity and specificity, but also the measurement of repeatability and 
reproducibility. Reproducibility assessments and standardization of the acquisition and 
data analysis methods are crucial when imaging biomarkers are used in multicenter trials 
for assessing response to treatment. Quality control in multicenter trials can be 
performed with the use of imaging phantoms or other techniques. The cost-effectiveness 
of imaging biomarkers also needs to be determined. Many imaging biomarkers are 
currently being developed, but there are still unmet needs—for example, in the detection 
of tumor invasiveness and migration, and dissemination, including the detection of 
micro-metastasis.  
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 A consensus statement was recently published to address the lack of validated 
imaging biomarkers shown in O’Connor et al. [53]. The need to validate potential 
imaging biomarkers requires quantitative molecular imaging protocols using well 
established and characterized animal models of cancer.  
 
1.5 Molecular Imaging Using micro-PET/CT 
 Today, many pre-clinical systems consist of a micro-PET and micro-CT 
subsystem for full whole-body imaging of rats and mice. Commercial units are provided 
by Perkin-Elmer, Sofie Biosciences, Mediso, Bruker, TriFoil Imaging, and MILabs Inc. 
All current modern micro-PET subsystems use silicon photomultipliers with a 3-D (x-y-
z) depth-of-interaction algorithm for an optimized line of registration. The nominal and 
maximum resolution of current modern micro-PET systems is 1 mm and 0.4 mm, 
respectively. On the other hand, the micro-CT subsystem consists of a variable or 
multiple fixed energy x-ray unit and a high-resolution flat panel detector. All current 
micro-CT subsystems generate images using cone-beam reconstruction algorithms 
(CBCT) [54]. The CT images are used for tissue characterization, PET attenuation 
correction and image fusion. All micro-PET/CT units have an integrated anesthesia and 
physiological monitoring system for each animal bed. Some systems with a large bore 
are capable of simultaneously scanning for up to four mice using an integrated 4-bed 
unit. All units are capable of quantitative imaging for 18F by transforming counts per unit 
volume into activity concentration (Bq/ml). The imaging systems have minimal quality 
control routines for CT, SPECT and PET to assure reliable data acquisition. However, 
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many systems are now upgrading the quality control routines by establishing a 
comprehensive quality assurance (QA) metrology package for quality control (QC). 
Figure 1 shows an overview of the Albira Si micro-PET/SPECT/CT unit that will be 
used for this research. 
 
 
Figure 1. An overview of the Albira Si micro-PET/SPECT/CT unit used in these 
studies. The system consists of 1) a micro-CT unit consisting of an x-ray and flat panel 
detector, 2) a 3-ring PET subsystem, and 3) a SPECT subsystem with two cameras. 
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2 MATERIALS AND METHODS 
 
2.1 Cone Beam Computed Tomography 
 Computed tomography (CT) is a radiological x-ray imaging technique which 
consists of an x-ray emitting source and a detector. Current clinical third and fourth 
generation scanners use a fan beam x-ray in combination with a large array of detectors 
across the fan width. The x-ray tube and detectors are rigidly linked and undergo single 
rotation motion.  As the emitted x-rays pass through an object, they are attenuated 
following the standard photon interactions: photoelectric absorption, coherent scattering, 
and incoherent scattering. The x-rays that make it through the object are measured at the 
detector and are used to generate projections at different angles of the object. To reject 
scatter radiation, current systems count with anti-scatter septa, which act as a grid. The 
reconstruction of the images is based on multiple methods and, in the majority of cases, 
each machine uses proprietary methods for image reconstruction. Independent of the 
reconstruction method, all systems need to be calibrated to respond invariantly to the 
same tissues encountered in the body. This means that no matter the reconstruction 
method, with the same input every machine should give the same output. Image 
reconstruction should provide an intrinsic and invariant attenuation coefficient for every 
voxel of an image.  Based on such a premise of invariance, Sir Godfrey Hounsfield 
established that all reconstruction methods should respond equivalently and thus 
established the Hounsfield Unit (HU). The HU value has a simple relationship with 
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water as a reference material.  The equation indicates that the values at each location, or 
voxel, in a CT image are normally given as  
 
HU = 	 (&m − &w)(&w − &a) ∗ 1000. (1) 
 
 Equation 1 shows how to calculate the Hounsfield Unit of a material using the 
total linear attenuation cross-section for the material, µm, water, µw, and air, µa. Using 
this equation, water will always have a HU value of 0 while air will always have a HU 
value of -1000 [56-58]. This allows for a consistent scale relative to the attenuation of 
water and for comparisons to be made across different machines and reconstruction 
algorithms. The use of the HU system is largely associated with clinical CT scanners 
using axial and helical tomographic methods.  
The characterization of tissue compositions using CT depends on multiple 
parameters, including effective x-ray energy and spectrum, detector system, acquisition 
parameters and reconstruction methods. Any reconstruction method should be invariant 
and estimate the effective photon attenuation coefficient of the tissues of a specimen, 
irrespective of location. However, there are significant variations in Hounsfield Units 
among different CT systems. The micro-CT subsystem of the Albira Si micro-
PET/SPECT/CT uses cone-beam CT (CBCT) as the scanning geometry. However, the 
application of the HU system in CBCT systems is controversial as it does not produce 
axial tomographic projections. Nonetheless, the HU system is still applicable for 
metrological purposes.  
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The x-ray unit of the micro-CT is an Apogee 5500 Series Model 93501 (Oxford 
Instruments, Oxfordshire, UK) running at 50 W, with energy range between 10 and 50 
kVp and two preset energy settings at 35 and 45 kVp. It runs with a maximum current of 
1 mA. The target is made of tungsten with an electron incidence angle of 12°. The focal 
spot is 35 µm. The system has filters of beryllium of 127 µm and aluminum of 500 µm.  
 The flat panel detector is a Hamamatsu digital flat panel model C7942CK-12 
using a single CsI crystal with a matrix of 2400 ´ 2400 pixels with 12-bit depth capable 
of 2 frames per second with no binning or 9 frames per second with a 4 ´ 4 binning. The 
pixel size is 50 ´ 50 µm and the resolution at 5% Contrast Transfer Function (CTF) is 
estimated at 8 line-pairs per mm.  The integral noise of the detector per normal 
acquisition is estimated at 1100 electrons per pixel. 
Reconstructed images have a nominal voxel resolution of 90 µm with a minimum 
of 5 µm. The field of view is 70 x 70 mm [55]. It is the latest emerging technique in 
computed tomography providing larger axial coverage, shorter scan time, isotropic 
spatial resolution, and better dose optimization. 
 
2.1.1 Phantoms Utilized in the Present Study 
 The characterization of any radiological imaging device requires the use of 
phantoms. In this study two phantoms were available for use. The first was the CIRS 
Model 62 electron density phantom that consists of 12 tissues in 25 plugs. These tissues 
were water, lung inhale and exhale, breast, adipose tissue, liver, muscle, trabecular bone, 
and 4 different dense bone tissues.  Figure 2 shows the phantom used in the present 
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study with internal and external plugs. The plugs were used in our studies as individual 
elements and they were place individually in the micro-CT.  
 
 
Figure 2. CIRS electron density phantom used to assess the HU using multiple plugs 
corresponding to different ICRU tissue equivalent materials. 
 
 
 The other phantom used in the present study was a micro-CT HA phantom 
(Quality Assurance in Radiology and Medicine, QRM, Munich, Germany) shown in 
Figure 3, which consisted of a single cylinder with 5 internal plugs of different 
hydroxyapatite (HA) densities of 0, 50, 200, 800 and 1200 mg cm-3.  The phantoms were 
used to compare potential discrepancies in the response of the micro-CT to size and 
geometry, x-ray potential (tube voltage), and calibration of the unit.   
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Figure 3. Micro-CT HA phantom used to assess the micro-CT response to different HA 
densities. The HA densities were 0, 50, 200, 800, and 1200 mg cm-3. Adapted from [59]. 
 
 
2.1.2 HU Linearity 
In preclinical scanners, linearity is a significant problem for dense bone 
structures as CBCT values are not equivalent to those obtained in clinical CT systems. 
The radio-density measured in CBCT is considered to be inaccurate because different 
areas of the scan may appear to have different greyscale values depending on their 
relative positions, even though both locations have the same density and composition 
[60].  Beam hardening results from the preferential absorption of low energy x-rays as 
they traverse the object. This effect makes the same tissue to appear with heterogeneities 
of the HU number and this correction for such artifact is necessary. This is referred as 
“cupping” artifact. This effect is intrinsic to CBCT systems and is not corrected yet by 
current reconstruction algorithms, such as COBRA (Exxim Computing Corporation, 
Pleasanton CA). The issues arise due to angular x-ray spectrum inhomogeneity, yielding 
different effective x-ray energies at different angles.  
HA 1200
HA 800HA 0
HA 200HA 50
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The HU values for different densities were estimated using five different bone 
electron density plugs from the CIRS phantom and the five different bone equivalent 
electron density locations in the QRM phantom, with each containing a different 
concentration of HA. These concentrations are 800, 1250, 1500 and 1750 mg cm-3 for 
the CIRS phantom and 0, 50, 200, 800, and 1200 mg cm-3 for the QRM phantom. A 
CBCT image of a dense bone plug and the QRM phantom are shown in Figure 4 below. 
 
 
Figure 4. a) CBCT axial image of the QRM micro-CT HA phantom showing the 
different HA plugs between 0 and 1200 mg cm-3. The diameters of the HA plugs are 5 
mm. b) CBCT axial image of the CIRS phantom plug with a HA plug of 1250 mg cm-3. 
The diameter of the bone plug is 10 mm.  
 
 
 For each phantom, the data was analyzed by drawing a circular ROI occupying 
more than ~70% of the diameter with the mean count recorded and tabulated along with 
its standard deviation. The mean counts are plotted against the concentration of HA for 
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statistical analysis. A linear relationship was expected to show that with a change in 
material concentration, there is a linear change in the HU value determined by the 
machine. If linearity is not achieved, it would mean that a change in HU value would not 
necessarily correspond to the same change in material composition or density.   
 
2.1.3 Image Uniformity and Noise 
 Image uniformity was visualized using a radial profile drawn over the 
reconstructed CT slices of a standard water phantom filled with distilled water. A 
volume rendering of the water phantom is shown below in Figure 5 along with the 
regions of interest (ROIs) that were used for image analysis. 
 
 
Figure 5. A volume rendering of a water uniformity phantom scan and the location of 
the five chosen ROI’s. 
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  For quantitative assessment, the mean difference in HU value between four 
peripheral ROIs and a central ROI was computed for the highest current setting, 1 mA, 
and the highest voltage potential, 45 kVp. The ROI size was approximately 0.92 mm3 in 
volume and placed in the north, east, south and west directions. The average difference 
between the outer ROI’s and the inner ROI needs to fall within ± 25 HU of the known 
value for water, a HU equal to 0. The center value alone must also fall within ± 20 HU 
of the known value for water. 
 Image noise is measured from the same five ROI’s that were chosen in the 
uniformity measurement and shown in Figure 5. It is the average of the standard 
deviation of the five ROI measurements above. 
 
2.1.4 Experimental Tissue Characterization and Uncertainties 
 The characterization of tissues based on the corrected HU values is fundamental 
to tissue phenotyping in small animal models of disease. Examples are those associated 
with animal models of obesity, where fat and lean tissue need to be differentiated, and 
osteoporosis, for the assessment of bone structures and density. This process of 
converting from the HU values of each voxel into material composition and densities 
was based on the measurements from the well-established phantoms. The use of 
corrected HU values for the characterization of tissues is a complex process that 
depends, on phantom size and geometry, x-ray voltage and calibration of the unit. Thus, 
every single micro-CT requires the analysis of the HU value of a given voxel(s) as well 
as those within a certain region surrounding it.  
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 The physical and electron density of these ICRU tissue equivalent plugs are 
shown in Table 1 below. A plot of the measured HU value with standard deviation 
versus the material density was created from this data. 
 
Table 1. CIRS electron density plug values including mass density, electron density and 
electron density relative to water [61]. 
Description Mass Density (g cm-3) 
Electron 
Density 
per cc  ´ 
1023 
RED 
(Relative 
to H2O) 
CIRS 
Phantom 
Lung (Inhale) 0.20 0.634 0.190 
Lung (Exhale) 0.50 1.632 0.489 
Adipose 0.96 3.170 0.949 
Breast (50% Gland / 50% Adipose) 0.99 3.261 0.976 
Water 1.01 3.346 1.002 
Muscle 1.06 3.483 1.043 
Liver 1.07 3.516 1.052 
Trabecular Bone (200 mg/cc HA) 1.16 3.73 1.117 
Dense Bone (800 mg/cc HA) 1.53 4.862 1.456 
Dense Bone (1250 mg/cc HA) 1.83 5.718 1.712 
Dense Bone (1500 mg/cc HA) 2.00 6.209 1.859 
Dense Bone (1750 mg/cc HA) 2.17 6.698 2.005 
QRM 
micro-CT 
Phantom 
Dense Bone (0 mg/cc HA) 1.13 NA NA 
Dense Bone (50 mg/cc HA) 1.16 NA NA 
Dense Bone (200 mg/cc HA) 1.26 NA NA 
Dense Bone (800 mg/cc HA) 1.65 NA NA 
Dense Bone (1200 mg/cc HA) 1.90 NA NA 
NA: Not available.  
 
2.1.5 Single Pixel Line Profiles 
 A single pixel line profile was taken in the transverse plane for the QRM micro-
CT HA phantom and all available density plugs. A single pixel line profile provides the 
real HU variability encountered among immediate voxels of a region of interest. 
Whereas line profiles can be obtained with multiple pixels the resulting average profile 
will be smooth but not representative of the real variations encountered in the image 
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data. Figure 6 shows an example of the line profile taken, which includes the air and the 
density plug. The line profile gives the value of each pixel from left to right.  By plotting 
these values through the different electron density phantoms, the difference in HU value 
from pixel to pixel across an image can be seen. The effect of beam hardening, the noise 
level, and tissue differentiation can all be observed from these plots. 
 
 
Figure 6. Line profile of a CIRS bone plug with concentration of 1750 mg cm-3. The 
profile shows the attenuation effects at the edge of the of the internal plug. 
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2.1.6 Theoretical HU Values as a Function of Material Composition 
 The HU values for the Albira Si micro-CT were estimated using the ICRU 
Report 46 [62] composition of the tissues representative in the CIRS Model 062 electron 
density phantom with material equivalent electron density plugs and the QRM micro-CT 
HA phantom. The HU values were calculated using the x-ray spectrum generated by the 
micro-CT using the corresponding electron angle of incidence, filters, and voltage 
potential. The software used to generate the spectrum was SpekCal [63-65]. Figure 7 
shows the x-ray spectrum generated for 35 and 45 kVp using an incent angle of 12 
degrees, 127 µm of Be, and 500 µm of Al.  The nominal spectra were used to determine 
the expected HU values of each of the tissue equivalent electron density plugs at the 
micro-CT levels. 
 X-ray mass attenuation coefficients were taken from XCOM on the NIST 
website using the provided tissue composition and energy spectrum values [66]. This 
produced a list of attenuation coefficients that could be normalized and used to compute 
the effective linear attenuation coefficient at the effective energy. Those values could 
then be plugged into Eq. 1 to calculate the HU and give an expected value for each 
tissue. 
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Figure 7. Calculated x-ray spectra for 35 and 45 kVp. The effective energies are 21.4 
and 24.8 keV respectively [63-65]. 
 
 
2.1.7 Nominal Absorbed Dose per Scan 
 Absorbed doses delivered to an animal during longitudinal studies by the micro-
CT subsystem are a significant issue as they become a confounding factor during 
therapeutic or diagnostic studies of radiopharmaceuticals, chemotherapeutics, and 
immunotherapeutics, which alters the effects of the drug or biomarker. Nominal 
absorbed doses need to be characterized to address this important confounding factor. A 
water phantom and an ionization chamber were used to assess the superficial and deep 
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dose for the CT at low and high current settings with high voltage. This was done as the 
worst-case scenario, meaning any dose received at other settings should not exceed these 
values. Calculations for cone-beam CT are simplified because the animal is fixed, and 
the CT system rotates without any pitch of the bed.  Therefore, two specific calculations 
are of significance in micro-CT, the surface dose and the deep dose. 
 All measurements were carried out using a calibrated ionization chamber from 
PTW, model TN31014, with a nominal activate volume of 0.015 cm3, working at +400 
V, with a 100% collection efficiency. The ionization chamber was calibrated using a 
60Co unit and the dose conversion factor, ND,W, was 2.412 ´ 109 Gy C-1.  The dose meter 
used was also calibrated at a National Voluntary Laboratory Accreditation Program 
(NVLAP) with a resulting uncertainty of 0.7% using a 137Cs source.  Dosimetry 
calculations were carried out following the AAPM Protocol for x-ray dosimetry in 
radiotherapy and radiobiology [67].   
 The x-ray spectrum that is observed by the flat panel detector changes as it 
passes through tissue (animal or object), which in turn hardens the primary spectrum. As 
an example, Figure 8 shows the nominal x-ray spectra for different attenuations through 
water showing the beam hardening of the original 45 kVp spectrum. The resulting 
changes are of significance as the average energy of the spectrum increases from 25 to 
32 keV. For this reason, both the superficial and deep doses needed to be measured as 
they each see different x-ray spectra, which deposits the dose at the target location.  
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Figure 8. Primary beam hardening of a nominal 45 kVp x-ray spectrum as a function of 
depth in water. The average energy of the spectrum was estimated at 25, 28, 30, 32 keV 
for 0, 1, 2.5, and 5 cm depth, respectively. 
 
 
2.2 Positron Emission Tomography 
 The micro-PET scanner in the Albira Si unit consist of three individual PET 
rings, with 8 modules per ring, totaling 24 modules. Each module has its own silicon 
photomultiplier (SiPM). The combination of continuous crystal, SiPM, and advanced 
electronics has led to a resolution of 0.7 mm with full field accuracy. The axial field of 
view is 148 mm and the transaxial view is 80 mm. It can image in three modes, static, 
dynamic, and dual cardiac/respiratory gated [55]. The National Electrical Manufacturers 
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Association (NEMA) established the NEMA Standard Publication NU 4-2008 
“Performance Measurements of Small Animal Positron Emission Tomographs,” which 
establishes the performance measurements of small animal tomography. The standard 
calls for the assessment of spatial resolution, sensitivity using a 22Na point source, 
Scatter Fraction, Count Losses, and Random Coincidence Measurements. However, it 
does account for radiation metrology of activity of specific radionuclides, such as 18F, 
124I, 64Cu, 62Cu, etc.  
 
2.2.1 Calibration and Uncertainties 
 The detection of photons is highly dependent on total activity, activity 
concentration, geometry, tissue attenuation and the generation of true, random, and 
scattered counts. A PET system will correct for these types of counts based on internal 
algorithms; however, the micro-PET subsystem requires that the system be calibrated to 
convert counts (counts/ml) into activity (Bq/ml). The micro-PET subsystem was 
calibrated using a cylindrical phantom with a nominal volume of 99 ml and a total 
activity concentration of 45473 kBq (1229 µCi). The micro-PET subsystem was allowed 
to acquire images for 5 min (300 sec) every 30 min for a total elapsed time of 12 hours. 
Images were reconstructed for a total of 19 data sets. The data is then analyzed using 
exponential decay and compared with the theoretical values from the decay of the 
radionuclide, in this study is 18F. The comparison between theoretical values and 
experimental results provides an estimate of the range of suitable activities and linearity 
of the system with corresponding errors. The uncertainties are used to assess the 
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suitability of the images obtained for a given scan and be converted into activity 
concentrations or SUV values.  
 
2.2.2 Resolution 
 A Derenzo phantom with different hot rod diameters will be used to measure the 
resolution, or line pairs per mm, of the micro-PET subsystem. Different activities and 
reconstruction parameters were run using the same phantom to compare the effects of 
increasing activity and increasing iterations, or reconstruction time. If these changes 
have an effect on the calculated activity concentration in a location or the standardized 
uptake value (SUV) they need to be communicated along with any information obtained 
from images. Otherwise the values are difficult to reproduce and verify. The basic 
equation for calculating SUV is 
 012 = 3(4 5⁄ ) . (2) 
 
In this equation r is the activity concentration in kBq ml-1, a is the decay-corrected 
activity to time of acquisition in kBq, and w is the weight of the subject in g. In clinical 
practice SUV values carry great uncertainty and difficult reproducibility as the amount 
of activity injected depends on many factors. The use of activity concentration tends to 
be a more reliable variable as it does not depend on the time of administration, uptake 
time, or uncertainties of activity measurements. For these reasons, activity 
concentrations will be used in this study.  
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2.3 micro-CT and micro-PET Image Registration 
 With each sub-system analyzed individually, the combination of their images and 
information also needs to be treated with the same precision. That includes how the 
images are co-registered or combined to overlay the images from the PET and the CT 
while both images do not actually occur in the same location. Bed movement is required 
to place the subject at both locations which can be inaccurate and lead to offset images 
in the three dimensions. Image fusion requires that both sets of data are co-registered in 
order to assign the activity distribution to the correct tissues and locations. 
Unfortunately, the resolution of CT images is higher than that of PET images causing 
mismatches in registration to become more relevant. The fusion of images requires that 
the virtual isocenter of the micro-PET and micro-CT be the same. The uncertainty in 
image fusion needs to be estimated when both data sets are registered. The isocenter for 
both systems will be established using a cross capillary set-up with a minimal activity 
associated with each. This method, however simple, requires that the capillaries be 
located within the field of view of each system and be within 2% of the same pixel 
locations. Co-registration is extremely important for Monte Carlo sampling to assign the 
correct activity concentration to the corresponding tissue sources. Discrepancies in co-
registration can lead to incorrect pharmacokinetic and dosimetry analysis of 
radiopharmaceuticals or activity on tissues and organs. 
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2.4 Computational Assessment of Subject Absorbed Dose 
 Once the CT and PET images have been quantified, they can be used to derive 
other values of importance to longitudinal studies using the micro-PET/CT, including 
the dose received for each individual study. To accomplish this objective, we developed 
a Python script where it reads DICOM images of both CT and PET to create an MCNP 
input deck for use in MCNP6 (version 6.1) [68]. From MCNP, the absorbed dose to each 
voxel can be calculated and used to generate plots of distributed absorbed dose to any 
collection of desired voxels for a given region of interest (ROI). 
 
2.4.1 Reading in a DICOM Image 
 The first step of the program is to give the location of the PET and CT image 
stacks and read in all of the required values needed for creating the input deck. For this 
program, the CT images should be placed in a folder titled “CT” and the PET images 
should be places in a file titled “PET”. These folders will always remain in the same 
location as the source code, and each time the program is to be run, the new images 
should be placed in their correct locations.  
 Using a package in Python, the images can be read, and any information stored in 
the DICOM images can be accessed. For this program we need the array values for each 
slice, the slice location, the pixel spacing, the number of rows and columns, the rescale 
slope, and the rescale intercept. The slice location allows the program to correctly order 
each slice no matter what order they are in in the folder. The pixel spacing gives the 
dimensions of each voxel in millimeters, which needs to be converted to centimeters for 
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use in MCNP. The number of rows and columns tells us how many voxels are in each 
slice and the number of files tells us how many slices we haves. The pixel values in a CT 
DICOM image are converted from HU values before being stored. Therefore, in order to 
convert these values back to HU, they need to be adjusted by the rescale slope and 
intercept before they can be used by the program. The pixel array for the PET data needs 
no conversions and can be used as imported because the data is used as a probability 
distribution of source location and will retain the same relative value. 
 
2.4.2 Creating an MCNP Run 
 A description of each major portion of the input deck is provided below with 
sample code provided for the reader. An in-depth description of how MCNP works is not 
covered, only a brief overview of the necessary parts to understand and run this code. 
Figure 9 below will be broken up between the next few sections to describe how this 
input deck works in the MCNP code. 
 
 
Figure 9. An Example MCNP input file. 
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Figure 9. Continued. 
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Surface Cards 
 While very long in length, this input deck is actually very simple. It contains only 
three surfaces, two boxes and a sphere. An example of the surface cards is shown below 
in Figure 10. 
 
 
Figure 10. Example surface cards used in the MCNP input deck. 
 
 
 Surface 1 is a box where the first three entries, (C1, C2, C3), are the (x, y, z) 
coordinates of the corner of the box, the second three entries, (X, 0, 0), are the vector of 
the first side, the next three, (0, Y, 0), the vector of the second side, and the last three, (0, 
0, Z), the vector of the third side. When (C1, C2, C3) is equal to (-X/2, -Y/2, -Z/2), you 
create a box centered at the origin with length X ´ Y ´ Z. Surface 1 is set to the size of a 
single voxel and surface 2 is set to the size of the total image, or the number of voxels in 
each direction times the size of the voxel in that direction. Surface 3 is a sphere oriented 
at the origin with a radius of length R, which is used to define the material universes 
discussed below. No other surfaces are needed in this input deck. 
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Cell Cards 
 A sample cell input is shown below in Figure 11. This is not what the final 
version of the MCNP input deck looks like but serves to accurately demonstrate the 
important points of the input deck. 
 
 
Figure 11. Example cell cards used in the MCNP input deck. 
 
 
 Cell 1, starting on the second line denoted with the number 1, is filled with 
material 1, which will be specified below, and a density of 1.205x10-3 g cm-3. The 
negative sign on the density value indicates that it is a mass density, as opposed to an 
atomic density which would be indicated with a positive value. All densities in this 
program are input as mass densities. The “-3” following the density indicates that this 
material fills the inside of surface three, which is described above as a sphere centered at 
the origin. This cell is stored as universe one, as indicated by “u=1”. For each material 
and density combination necessary in the input deck, there will be a specific cell and 
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universe that corresponds to it. In the example code there are two materials, indicated by 
cells one and two. Following these is a cell, cell three, which is filled with void, 
indicated by 0, and is contained inside surface one, which is the voxel box. This cell is a 
lattice made up of hexahedra’s, or cubes. It contains cubes located at position (-255, -
255, -106) all the way to (256, 256, 106), or 512 x 512 x 213 = 55,836,672 voxels. The 
“&” at the end of the line indicates that the input continues onto the next line which 
describes the universe which fills each position on the lattice. A “1” indicates universe 
one while a “2” indicates universe 2. A number with an “r” attached to in, as in “48370r” 
means that the previous position, in this case position 1, should be repeated 48,370 more 
times. This format was used to reduce the memory size of the input files created since 
every voxel did not necessarily need to be explicitly written. The positions fill from (-
255, -255, -106) to (-254, -255, -106) through all 512 x-direction positions before 
incrementing once in the y-direction. Once all 512 y-direction positions have been filled, 
it then increments once in the z-direction position. Figure 12 is a visual example of how 
the lattice positions are filled.  
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Figure 12. An example of how the lattice fills, starting from position 1 and ending with 
position 16. It first increments along the x-direction, then increments along the y-
direction, and finally in the z-direction. 
 
 Cell four puts our lattice structure inside our box which is the size of the total 
image and cell five makes everything outside of the total image box void. In this way, 
any particle that leaves the volume defined by the total image box will no longer be 
tracked by MCNP.  The material of each voxel is decided by the value of the pixel array 
at that location in the DICOM slice. In this way the image is recreated voxel by voxel in 
MCNP. 
 
Material Specification 
 Material composition and ranges were determined using the results from 
Schneider et al. [69]. They gave equations for density across the range of HU values as 
well as a table of different HU values and their compositions. Their table was converted 
from HU values to density ranges. These density ranges were compared to the plot 
x 1st
y 2nd
z 3rd
1 2 3 4
5 6 7 8 12
16151413
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generated in from the Tissue Characterization and Uncertainty section. This redistributes 
their HU ranges into the HU ranges for the Albira Si machine. The material specification 
lines of the input deck are shown below in Figure 13. 
 
 
Figure 13. Example material cards used in the MCNP input deck. 
 
 The first material, “M1”, represents dry air while material two, “M2”, represents 
water. The values following the material numbers are in the form of ZAID numbers 
where the first number is the atomic number of an element, or Z, followed by the mass 
number, or A. If the natural abundance of an element is desired, then a mass number of 
“000” should be used.  
 For example, the ZAID number of natural hydrogen would be 1000. The value 
following the ZAID number is the atomic fraction, or weight fraction if entered with a 
negative sign, and indicates the fraction of the material which is composed of the 
preceding element. The “PLIB” and “ELIB” entries specify the libraries from which the 
photon and electron data libraries should be acquired. If “GAS” is set equal to one, it 
indicates that the material should be in a gas state. If it is set to zero or not specified, 
then the material should be treated as a solid or liquid. 
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Source Specification 
 In this code the decay of 18F was modeled as the radioactive source in the 
problem. It decays by positron emission 96.7% of the time with an energy of 249.8 keV, 
and by electron capture 3.3% of the time emitting either an Auger electron with energy 
0.52 keV, an x-ray with energy 0.5249 keV, or an x-ray with energy 0.5 keV. It has a 
half-life of 109.77 minutes and its daughter, 18O, is stable. The pixel array of the PET 
gives the relative distribution of the source throughout the body and can therefore be 
used as the probability of a particle being emitted from a certain location relative to 
every other location in the geometry. 
 An example of the source distribution used in this code is presented in Figure 14 
below. 
 
 
 
Figure 14. Example source cards used in the MCNP input deck. 
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 The “SDEF” line indicates the variables of the source in the geometry including 
“PAR”, the particle type emitted, “CEL”, the cell in which the particle should start in, 
and “ERG”, the energy of the particle started. The cell and particle type variables are 
each given by a distribution, “D2” and “D3” respectively, while the energy distribution, 
“D1”, is a distribution dependent on the variable particle type, indicated by “FPAR”. 
The particle type distribution is described by “SI3” and “SP3”. The source information 
card “SI” gives the discrete variable values while the source probability card “SP” gives 
the probability for each discrete variable. In this example, the emitted particle can be one 
of four options, two type two particles, a type three particle, or a type eight particle. 
Type two is a photon, type three is an electron, and type eight is a positron. The emission 
probabilities of these particles are 4.74x10-10 %, 1.8x10-2 %, 3.07 %, and 96.7 % 
respectively. The energy distribution depends on which particle is emitted, therefore 
tying the correct emission energy with the different decay paths. 
 The cell description is given by “SI2” and “SP2”. In this example, every cell is 
included in the distribution and the PET pixel data is used to give the probability that a 
source is emitted from that particular voxel. The exact starting location for a source 
particle is randomly distributed inside whichever cell is chosen for the particle to be born 
in. This is because while the activity concentration of the PET tracer inside a certain 
voxel is known, it cannot say from which location inside that voxel the particles were 
emitted from. 
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Physics 
 An example of the physics cards used in the input deck are given below in Figure 
15. The “mode” line indicates that the program will track both photons, “p”, and 
electrons “e”, but not neutrons. The program treats positrons similar to electrons and will 
therefore track them as well. 
 
 
Figure 15. Example physics cards used in the MCNP deck. 
 
 The cut cards indicate the energy below which particles will no longer be 
tracked. Both photons and electrons will only be tracked down to 20 eV. All other 
physics interactions are left at their default settings for the program. 
 
Tallies 
 An *F8 tally is used in this input deck to calculate the energy deposited in each 
lattice position or voxel and can be seen in Figure 16 below. 
 
 
Figure 16. Example Tally card used in the MCNP deck. 
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 The asterisk before “f8” indicates that the tally result should be given in units of 
MeV. The tally tracks the energy deposition by both photons and electrons by the “p,e” 
following the tally call. The “(3<3[-256:256 -256:256 -106:106])” indicates the locations 
in the lattice that the tally should occur in. It gives an individual energy deposition tally 
for each cell listed, which in this case is every cell in the lattice. 
 
Output 
 The results of the tally in MCNP are printed to the output file with the tally 
statistics as well as the warnings, comments, and information about the MCNP run. The 
tally results are also printed to a separate file in ASCII format. This separate ASCII file 
is used to read in the results for each lattice or voxel position. Each voxel position has a 
value for the energy deposited per starting particle in MeV and the relative error of the 
energy deposited. These values are read into arrays, one containing the energy and one 
containing the error. Each position in the energy array is divided by the mass of that 
particular voxel in grams, which depends on the material designation from the MCNP 
input deck. This converts the energy array into a dose array with units of MeV per gram 
per starting particle. The unit of starting particle can be replaced with the unit of Bq s, or 
decays. Multiplying by 1.602 ´ 10-10 converts this into units of Gy Bq-1 s-1. This array is 
saved in the DICOM format and can be loaded into any image viewing software for 
analysis. 
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2.4.3 Imaging Studies 
 Two different studies were analyzed to determine dose and verify that the energy 
distribution follows as expected based on the tracer type injected. The first study is the 
tracer Fludeoxyglucose ([18F]FDG) injected retro-obritally while the second is the tracer 
sodium fluoride ([18F]NaF) injected by tail vein injection. Each PET image and 
corresponding CT image is used to create an MCNP input deck. That deck is run and the 
resulting energy deposition per voxel is determined and saved in the DICOM image 
format. These images can then all be loaded into a program like ITK-SNAP and 
segmentation can be done to determine the dose to any desired collection of voxels. In 
this way, if the user would like to change the segmentation a new MCNP run is not 
necessary to recalculate the dose to the new collection of voxels. 
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3 RESULTS 
 
 Based off of the materials and methods described above the data was gathered 
and plots were generated. These are provided below with a discussion on the major 
implications occurring in Section 4. 
 
3.1 Cone Beam Computed Tomography 
 The CBCT unit was used to quantify the characteristics of the machine for use in 
pre-clinical studies. The results are discussed in the following subsections. The 
acquisition quality depends on the number of projections resulting in different exposure 
time and final reconstructed voxel size. The reconstruction of the data is carried out 
using the proprietary reconstruction code COBRA (Exxim Computing Corporation, 
Pleasanton CA).  The number of projections is substantial as a cone beam CT is being 
used and a fraction of the field of view is being used for reconstructing the 3D volume.  
Table 2 shows the available CT acquisition parameters for the micro-CT subsystem. 
 
Table 2. Nominal CT acquisition specification parameters. 
Acquisition Quality Projections Approximate Exposure Time (min) Voxel Size (µm) 
Standard 250 3 500 
Good 400 5 250 
Best 600 8 125 
High Resolution 
(For ex-vivo imaging 
only) 
1000 10 35 
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3.1.1 Linearity 
 Using the trabecular bone and four dense bone plugs the HU values for the 
Albira Si CT machine were tabulated at 35 and 45 kVp for the CIRS phantom and are 
shown below in Table 3. 
 
Table 3. Linearity values measured from the Albira Si micro-CT at 35 and 45 kVp using 
CIRS model 62 bone equivalent phantoms plugs with differing HA densities. 
Bone Tissues 
HA 
Concentration 
(mg cm-3) 
35 kVp 45 kVp 
Measured 
Mean HU 
HU 
Standard 
Deviation 
Measured 
Mean HU 
HU 
Standard 
Deviation 
Trabecular Bone 0200 0319.61 024.80 318.06 24.69 
Dense Bone 
0800 0619.50 065.79 610.54 19.76 
1250 0891.82 159.85 739.30 42.89 
1500 0996.34 213.61 834.20 42.83 
1750 1090.83 271.76 899.57 53.42 
 
 
 Table 4 shows the HU values for the five plugs in the QRM phantom at 45 kVp. 
While the concentrations differ between the two phantoms they do share one point in 
common, 800 mg cm-3, and have another relatively close to each other, ~1200 mg cm-3. 
From inspection these values do not fall within two standard deviations of each other 
and can therefore be considered different values. 
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Table 4. Linearity values measured from the Albira Si micro-CT at 45 kVp using the 
QRM-HA phantom. 
Bone Tissues 
HA 
Concentration 
(mg cm-3) 
45kVp 
Measured 
Mean HU 
HU 
Standard 
Deviation 
Dense Bone 
050 065.31 7.25 
200 0254.55 8.18 
800 0828.99 40.19 
1200 1169.3 52.5 
 
 
 These results are also plotted with a linear line of best fit in Figure 17 below. The 
R2 values for the lines of best fit area 0.99595, 0.98104, and 0.99752 for the CIRS 35 
kVp, CIRS 45 kVp, and the QRM 45 kVp phantom images respectively. While all of the 
images have a linear trend to them the data for the 1250 mg cm-3 value for 45 kVp lies 
much further from the line than the rest of the points do. This is indicated by an R2 value 
closer to 1, for the CIRS 35 kVp and QRM 45 kVp lines. For all cases, with an R2 above 
0.95 it can confidently be said that the data follows a linear trend. 
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Figure 17. A plot of the HU values of bone equivalent phantoms with different densities 
of HA inside the CIRS and QRM phantoms with a linear regression fitted to each. The 
R2 values for the lines of best fit are 0.99595, 0.98104, and 0.99752 for the CIRS 35 
kVp, CIRS 45 kVp, and the QRM 45 kVp phantoms respectively. 
 
 
 This conclusion should allow for values in the HU range of bone to be compared 
and interpreted without worry that the values are incorrect or misleading. Since the 
machine calibration occurs between air and water it can also be assumed that those HU 
value areas also follow an accepted linear trend. All of this is to say that the values 
produced by this machine should be comparable and represent a real change in density 
and/or material composition no matter where on the HU range the value should fall. 
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3.1.2 Image Uniformity and Noise 
 Using the water phantom with 5 ROI’s drawn inside of the water region of the 
phantom and one region drawn outside in the air, the results in Table 5 were calculated. 
 
Table 5. Uniformity values measured in a water phantom at the center and four 
directions. 
ROI Location ROI Size (mm3) Mean HU 
HU Standard 
Deviation 
Difference from 
Center 
Air 0.92456 -1000 0.00  
Center 0.92395 03.895 19.468  
North 0.92395 26.423 27.527 22.527 
East 0.92395 18.503 22.822 14.608 
South 0.92395 22.270 25.163 18.374 
West 0.92395 25.889 28.758 21.993 
Average Difference from Center 19.376 
 
 
 The effects of the CBCT can be seen in the above table. While every location 
contains only distilled water, the center location has an HU value of 3.895 while every 
directional location has an HU value in the range of 18 to 27. It can also be seen that the 
error of the values located towards the outer regions of the image is greater than that of 
the center value. This shows the effect of the CBCT, where voxel locations towards the 
outer regions are deemed to have a higher attenuation value than the same material 
located in the center of the image. When viewing images and conducting segmentation 
this increase in HU values towards the outer regions of the image could have a major 
effect on the classification of those voxel positions. 
 An average distance from the center value of 0 ± 25 HU and a center value of 0 ± 
20 HU is acceptable and considered a pass by the system calibrations. By definition this 
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scan was acceptable and passed the required quality control checks with a value of 
19.376, but the user should continue to monitor the calibration. If this value begins to 
shift significantly further than its current location, values taken from the image will not 
be deemed reliable. 
 
3.1.3 Experimental HU Values as a Function of Material Composition 
 The tissue equivalent electron density plugs were measured individually in the 
micro-CT machine and their mean HU values are shown in Table 6 and Table 7 below. 
This data is also plotted in Figure 18 with a linear line that intersects the values for both 
air and water. 
 
Table 6. Electron density phantom measured HU values for each CIRS plug. 
Tissue 
Mass 
Density 
(g cm-3) 
35 kVp 45 kVp 
Measured 
HU 
Standard 
Deviation 
Measured 
HU 
Standard 
Deviation 
Air 0.00121 -1000 0 -1000 0 
Inhale 0.20 -935.51 069.36 -938.79 61.10 
Exhale 0.50 -316.95 050.02 -381.39 35.37 
Adipose 0.96 0-72.91 024.76 0-68.38 21.28 
Breast 0.99 0-23.00 011.50 0-25.43 11.28 
H2O Equivalent 1.01 0055.53 048.51 0039.26 35.80 
Muscle 1.06 0098.54 043.86 0086.37 39.32 
Liver 1.07 0108.67 039.66 0107.11 35.87 
Trabecular Bone 1.16 0319.61 024.80 0318.06 24.69 
Dense Bone 1.53 0619.50 065.79 0610.54 19.76 
Dense Bone 1.83 0891.83 159.85 0739.30 42.89 
Dense Bone 2.00 0996.34 213.61 0834.20 42.83 
Dense Bone 2.17 1090.83 271.76 0899.57 53.42 
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Table 7. Electron density phantom measured HU values for each QRM plug. 
Tissues Density  (g cm-3) 
45kVp 
Measured 
Mean HU 
HU 
Standard 
Deviation 
Dense Bone 1.13 -16.66 6.7 
Dense Bone 1.16 65.31 7.25 
Dense Bone 1.26 254.55 8.18 
Dense Bone 1.65 828.99 40.19 
Dense Bone 1.90 1169.32 52.5 
 
 
 
Figure 18. A plot of the measured HU values for the electron density plugs versus their 
density for the micro-CT. 
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 It can be seen in the figure above that all of the data fall within range of the line 
except for the inhale, exhale, and trabecular bone. This is not the expected trend for 
these materials. Figure 19 shows the plot of the same electron density plugs measured in 
a clinical machine at 70 and 140 kVp. 
 
 
Figure 19. A plot of the same electron density plugs scanned on a Siemens Somatom 64 
clinical CT machine. 
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 This figure shows the expected trend, where in the region of bone, HU > 300, 
there is a greater rise in the HU value with the same change in density as there would be 
in the tissue region. 
 
3.1.4 Electron Density Phantom Line Profiles 
 The single pixel line profiles for each tissue equivalent phantom are plotted in 
Figure 20 below. The images have been plotted only across the region of the image 
which contains the phantom while the imaging bed and air are not included in the plots. 
The amount of noise in the image along with the cupping artifact from the CBCT can 
easily be seen in sharp changes from one pixel to another and by the lower HU values in 
the center of the image compared to on the outer edges of the image. The statistics of 
each tissue equivalent plug are presented in Table 8. 
 From the plots and table, it can be seen that material differentiation is possible 
but in certain regions cannot be as precise as clinical CT machines. For example, in the 
range of tissues, -100 < HU < 150, muscle and liver tissues can be distinguished from 
adipose and breast tissues. However, since adipose and breast tissue ranges overlap each 
other, when looking to differentiate between each specific tissue type, a confident 
statement cannot be made about which material is being viewed.  The same can be said 
for muscle and liver tissue, as well as dense bone at the outer regions of the plot. 
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Figure 20. Single pixel line profiles through the CIRS phantom tissue equivalent plugs. 
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Table 8. Average, standard deviation, minimum, and maximum values for line profiles 
across each tissue equivalent phantom. 
Tissue Equivalent 
Average 
HU Value 
Standard 
Deviation 
Minimum HU 
Value 
Maximum HU 
Value 
Inhale -937.79 52.15 -1000.00 -790.73 
Exhale -383.16 36.71 -493.18 -277.77 
Adipose -75.48 23.07 -134.34 -26.24 
Breast -28.69 13.97 -79.38 -4.85 
Water 45.14 42.91 -13.14 138.49 
Muscle 86.75 39.24 4.00 149.01 
Liver 98.94 39.80 -6.53 155.28 
Trabecular Bone 309.95 30.42 243.04 412.52 
Dense Bone 800 595.60 61.67 261.99 663.50 
Dense Bone 1250 706.07 108.95 201.64 857.04 
Dense Bone 1500 810.61 117.36 293.05 998.73 
Dense Bone 1750 870.86 149.46 245.59 1111.20 
 
 
  
Figure 21. A single pixel line profile through a mouse subject. 
 
 
 Figure 21 shows a single pixel line profile, similar to those through the tissue 
equivalent phantoms, with the data plotted alongside the CBCT image. This line profile 
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runs across areas of both bone and tissue with HU values ranging from around 0 to 
approximately 500. While the noise levels and cupping artifacts appear to have a large 
effect in the tissue equivalent phantoms, it cannot readily be seen in the mouse line 
profile. This is true even when moving across different material boundaries. Further 
discussion on this topic will be covered in Section 4 below. 
 
3.1.5 Theoretical HU Values as a Function of Material Composition 
 Using the photon energy spectrums, the material composition lists from ICRU, 
and the total linear attenuation coefficients obtained from NIST: XCOM an expected HU 
value can be calculated for each material. The results of this calculation are shown below 
in Table 9. 
 This table contains materials that should correspond to the tissue equivalent 
electron density plugs that are measured and discussed in the previous sub-section. 
These are the values that are expected from the measurements. Lung is expected to be in 
the region between exhale and inhale, trabecular bone should be similar to spongiosa and 
cortical bone should fall in the dense bone region between the 1.83 and 2.0 g cm-3 
density plugs. Figure 22 shows the expected HU values plotted versus their density for 
both voltage potentials and a linear line which crosses through air at -1000 HU and water 
at 0 HU. 
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Table 9. ICRP tissues with the expected HU values calculated for each voltage of the 
micro-CT. 
Tissue 
⍴ n0 Expected HU Value 
kg m-3 m
-3 ´ 
1026 35 kVp 45 kVp 
Adipose tissue     
Adult #1 970 3240 -295.90 -279.33 
Adult #2 950 3180 -352.72 -333.77 
Adult #3 930 3120 -409.09 -387.80 
Breast (whole)-50/50 (water/lipid) 960 3220 -248.70 -235.63 
Liver     
Adult (healthy) 1060 3510 79.36 78.28 
Adult (fatty) 1050 3480 35.72 36.74 
Adult (cirrhotic) 1040 3450 -0.83 1.88 
Lung     
Adult (healthy) 260 862 -733.98 -734.38 
Adult (congested) 1040 3450 67.81 66.21 
Muscle (skeletal)     
Adult 1050 3480 62.07 61.45 
Skeleton-cortical bone     
Adult 1920 5950 8644.30 8224.56 
Skeleton-spongiosa Adult 1180 3840 1588.81 1514.17 
Water 1000 3340 0.00 0.00 
Air 1.205  -1000.00 -1000.00 
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Figure 22. The expected HU values for the CIRS phantom plotted against their densities 
for voltage potentials of 34 and 45 kVp. A linear line is also plotted which passes 
through air at -1000 HU and water at 0 HU, and another through water at 0 HU and 
dense bone at ~8000 HU. 
 
 
 Comparing these values to expected values from an above subsection yields 
varying results. Since air is one of the calibration points for the machine, that value 
matches perfectly. Lung, muscle, and liver all fall within error of their calculated values 
from ICRU. Adipose, breast, and bone are well outside the error ranges for their 
corresponding materials from ICRU. Using the equation for calculating the HU value 
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and using the linear attenuation coefficient for bone at different energies it was 
determined that the effective energy which would have yielded correct results was above 
140 keV. For an x-ray machine with a maximum operating voltage potential of 50 kVp 
this is not possible. It was concluded that the CT subsystem uses a calibration which 
causes the bone to fall on the same linear trend line as the region between air and water, 
which for clinical CT scanners is not the case. 
 
3.1.6 Nominal Absorbed Dose per CBCT Scan 
 Using the water phantom and the PTW ionization chamber described before, the 
surface and deep absorbed dose were estimated for the 45 kVp setting. The results for 
both the superficial- and deep-dose equivalent measurements at low and high current 
settings and high voltage are shown in Figure 23 and Figure 24 below. 
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Figure 23. The superficial-dose equivalent over time for a low and high current scan at 
the highest voltage setting. The slopes for the linear fits are 0.2979 mGy s-1 for the low 
current and 0.5957 mGy s-1 for the high current. Both y-intercepts are 0. 
 
 
 
Figure 24. The deep absorbed dose equivalent over time for a low and high current scan 
at the highest voltage setting. The slopes for the linear fits are 0.1833 mGy s-1 for the 
low current and 0.3667 mGy s-1 for the high current. Both y-intercepts are 0. 
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 Using the linear trend lines fit to the data the total dose can be calculated for each 
type of scan, as long as the scanning time is known. These values are shown in Table 10 
and can be used during longitudinal studies to track the dose received for each animal 
over the multiple scan sessions. 
 
Table 10. The superficial- and deep-dose equivalent vales for low and high current 
settings at the maximum voltage, 45 kVp. 
 Superficial Dose Equivalent (mGy) Deep Dose Equivalent (mGy) 
 Low Current High Current Low Current High Current 
Standard 
(3 min) 53.6 107.2 33.0 66.0 
Good 
(5 min) 89.4 178.7 55.0 110.0 
Best 
(8 min) 143.0 285.9 88.0 176.0 
High Resolution 
(10 min) 178.7 357.4 110.0 220.0 
 
 
 If there was a longitudinal study that required a total of five scans, at the lowest 
setting of resolution, 500 µm, and current, the total superficial dose would be 0.268 Gy 
and the deep dose would be 0.165 Gy. 
 
3.2 Positron Emission Tomography 
 The PET unit was used to measure the calibration and uncertainties of the 
machine along with the partial volume effects. The results of the studies are discussed in 
the following subsections. 
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3.2.1 Calibration and Uncertainties 
The calibration of the micro-PET requires a uniformity phantom based on a 
cylinder. Figure 25 shows an image of the resulting long uniformity phantom (99 ml) 
used for calibration purposes. The images show uniform distribution over the whole 
phantom with minimal uncertainties, which were quantitated for calibration purposes. 
Acquisitions were obtained at different time points to assess the uniformity and response 
as a function of activity concentration. The region of interest (in pink) in the image 
corresponds to that analyzed for establishing the Q value of the system. No significant 
variations were observed as a function of RIO size.   
 
 
Figure 25. Long uniformity phantom used to assess the Q value for the micro-PET 
system. 
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 The initial activity in the phantom was 45473 ± 909 kBq at the time of 
calibration. Once the phantom is in the system, it calculates the activity at the 
corresponding elapsed time of image acquisition from calibration time for every frame 
and provides the corresponding activity concentration at midpoint. The duration of each 
scan was 300 s and the midpoint of each scan was 150 s. The Q value is then calculated 
by inspecting the data for linearity, selecting the range of data (activity concentrations) 
where the system is linear, and using linear regression analysis, assess the corresponding 
Q value and corresponding uncertainty. The Q value of the system needs to be under 
quality control based on quality assurance standards that indicate that the systems is 
stable when the variations within calibrations (QC) do not deviate from 5%. 
 The resulting values are presented in Table 11 and are plotted in Figure 26 with a 
linear trend line between counts per unit volume and activity concentration. Three 
different regions can be observed including regions of saturation, under response, and 
supra-linearity. The micro-PET system was found to be linear for activity concentration 
below 25 kBq/ml with a saturation limit of 100 kBq/ml. Therefore, the micro-PET 
subsystem can only be considered to be quantitative when total activities are less than 
the saturation limit of 7.4 MBq (200 µCi). 
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Table 11. Data obtained for multiple frames used to calculate the Q value of the micro-
PET system. 
Frame Time (s) Mean Counts 
Standard 
Deviation 
Concentration 
(kBq/ml) 
Standard 
Deviation 
0 5010 1.71 ´ 10-3 4.10 ´ 10-4 271.140 65.10 
1 7110 9.91 ´ 10-4 1.45 ´ 10-4 217.388 31.78 
2 9210 1.02 ´ 10-3 1.20 ´ 10-4 174.293 20.53 
3 11310 1.13 ´ 10-3 1.14 ´ 10-4 139.741 14.05 
4 13410 1.16 ´ 10-3 1.14 ´ 10-4 112.038 10.97 
5 15510 1.11 ´ 10-3 1.09 ´ 10-4 89.828 8.82 
6 17610 1.02 ´ 10-3 1.03 ´ 10-4 72.020 7.33 
7 19710 9.01 ´ 10-4 9.82 ´ 10-5 57.743 6.29 
8 21810 7.69 ´ 10-4 8.90 ´ 10-5 46.296 5.36 
9 23910 6.49 ´ 10-4 8.04 ´ 10-5 37.118 4.60 
10 26010 5.36 ´ 10-4 7.47 ´ 10-5 29.760 4.15 
11 28110 4.43 ´ 10-4 6.75 ´ 10-5 23.860 3.64 
12 30210 3.61 ´ 10-4 6.03 ´ 10-5 19.130 3.19 
13 32310 2.96 ´ 10-4 5.49 ´ 10-5 15.338 2.85 
14 34410 2.39 ´ 10-4 4.84 ´ 10-5 12.297 2.49 
15 36510 1.92 ´ 10-4 4.34 ´ 10-5 9.859 2.22 
16 38610 1.55 ´ 10-4 3.96 ´ 10-5 7.905 2.02 
17 40710 1.26 ´ 10-4 3.61 ´ 10-5 6.338 1.82 
18 42810 1.00 ´ 10-4 3.30 ´ 10-5 5.081 1.68 
19 44910 8.05 ´ 10-5 2.92 ´ 10-5 4.074 1.48 
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Figure 26. Performance characteristics of the Albira micro-PET showing the mean 
count per unit volume as a function of activity concentration. The response is not linear 
at activity concentration higher than 50 kBq ml-1, showing a saturation activity 
concentration about 80 kBq/ml, the system becomes supra linear at activity 
concentration higher than 250 kBq ml-1.  
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3.2.2 Resolution  
The spatial resolution of the micro-PET system was estimated using a modified 
Derenzo phantom where the activity, acquisition time and MLEM iterations were tested. 
The diameters of the hot rods of the modified Derenzo phantom were 0.75, 1.0, 1.35, 
1.70, 2.0, and 2.4 mm. Figure 27 and Figure 28 show the transaxial images of the 
Derenzo phantom where the best resolution was 0.75 mm using a minimum of 100 
iterations.   
 
 
  
Figure 27. Resolution of the Albira micro-PET system using a Derenzo phantom. a) 
Acquisition time: 5 min, 17760 kBq (480 µCi), MLEM: 12 iterations, voxel size 0.4 
mm. b) Acquisition time: 2 h, activity 10767 kBq (291 µCi), MLEM: 120 iterations, 
voxel size 0.4 mm. 
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Figure 28. Resolution of the Albira micro-PET system using a Derenzo phantom at 
different iteration levels. Acquisition time: 2 h. Activity 10767 kBq (291 µCi), voxel 
size 0.4 mm. 
 
 
 It can be seen from Figure 27 that having a higher total activity concentration 
does not assure a better resolution, as there will be more artifacts associated with 
sensitivity, scatter and random counts. Lower activity and a higher number of iterations 
(longer reconstruction times) provides better resolution and lower partial volume effects. 
 
3.3 micro-CT and micro-PET Image Registration and Uncertainty 
 After individual quantification of each machine, the micro-PET/CT unit was used 
to measure the co-registration and uncertainty of the individual imaging modality 
images. The co-registered image of the CBCT and the PET from the cross-capillary 
study and the single pixel line profile comparison of the two units are shown in Figure 
29 and Figure 30 below. 
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 Transverse Coronal Sagittal 
Figure 29. Single pixel line profile through cross capillaries used to assess the Dx, Dy, 
and Dz displacement to attain co-registration of PET and CT images.  
 
 
  
  
Figure 30. Single pixel line profiles for both the PET and CT images for the assessment 
of Dx, Dy, and Dz displacement using the cross-capillaries study. A cubic spline function 
was used to determine the maximum peaks for the different line profiles.  
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 It can easily be seen that the PET and CT images give different ranges for the 
size and position of the capillaries in the image. This particular line was chosen because 
it crossed the capillaries at multiple locations in the same line. Since the line is so close 
to the center cross of the capillaries, the PET values never return to zero even though the 
line crosses through a collection of air before crossing another capillary. A distribution 
of PET tracer can also be seen in the first capillary crossing where there are two peaks in 
a location only one would be expected. This is due to improper filling of the capillaries 
with the PET tracer.  While the peaks do not line up exactly, when considering only 
values above 1% of the total counts in the PET line profile, the peaks of the PET and CT 
fall within an acceptable range. The displacement was estimated as the average of at 
least two points given their minimum and maximum values. In the x axis the 
displacement was estimated at 0.405 mm (0.39 mm – 0.42 mm), in the z axis was 
estimated at 0.21 mm (0.19 mm – 0.23 mm), and in the y axis was 0.15 mm (0.14 mm – 
0.16 mm). These displacement values are provided into the header of the images to 
attain co-registration when the images are superimposed.  There is no rotation algorithm 
at the present moment as it is assumed that the z axis corresponding to the table 
movement is linear.  However, we have noticed that the weight of the animal does affect 
the coronal plane due to a significant tension on the bed as it moves inside the CT unit. 
To correct for this potential issue a study cradle for the animal bed is currently being 
design.  
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3.4 Computational Assessment of Subject Absorbed Dose 
 As described above, two studies were run in MCNP to calculate the dose per 
voxel for both [18F]FDG and [18F]NaF. 
 
Table 12. A breakdown of the division of HU values into material bins with the 
composition and density give. These divisions are used to divide the CT values into 
materials for use in the MCNP program. 
MCNP 
Material 
Number 
HU Range 
(min, max) 
 r 
(g cm-3) 
Composition 
H C N O Na Mg P S Cl Ar K Ca 
1 -1000, -950 0.00121   75.5 23.2      1.3   
2 -950, -125 0.48 10.3 10.5 3.1 74.9 0.2  0.2 0.3 0.3  0.2  
3 -125, -90 0.93 11.6 68.1 0.2 19.8 0.1   0.1 0.1    
4 -90, -55 0.96 11.3 56.7 0.9 30.8 0.1   0.1 0.1    
5 -55, 0 0.98 11 45.8 1.5 41.1 0.1  0.1 0.2 0.2    
6 0, 50 1.01 10.8 35.6 2.2 50.9   0.1 0.2 0.2    
7 50, 65 1.03 10.6 28.4 2.6 57.8   0.1 0.2 0.2  0.1  
8 65, 120 1.06 10.3 13.4 3 72.3 0.2  0.2 0.2 0.2  0.2  
9 120, 180 1.09 9.4 20.7 6.2 62.2 0.6   0.6 0.3    
10 180, 270 1.11 9.5 45.5 2.5 35.5 0.1  2.1 0.1 0.1  0.1 4.5 
11 270, 340 1.17 8.9 42.3 2.7 36.3 0.1  3 0.1 0.1  0.1 6.4 
12 340, 380 1.22 8.2 39.1 2.9 37.2 0.1  3.9 0.1 0.1  0.1 8.3 
13 380, 415 1.28 7.6 36.1 3 38 0.1 0.1 4.7 0.2 0.1   10.1 
14 415, 450 1.34 7.1 33.5 3.2 38.7 0.1 0.1 5.4 0.2    11.7 
15 450, 485 1.40 6.6 31 3.3 39.4 0.1 0.1 6.1 0.2    13.2 
16 485, 520 1.46 6.1 28.7 3.5 40 0.1 0.1 6.7 0.2    14.6 
17 520, 555 1.52 5.6 26.5 3.6 40.5 0.1 0.2 7.3 0.3    15.9 
18 555, 590 1.58 5.2 24.6 3.7 41.1 0.1 0.2 7.8 0.3    17 
19 590, 625 1.64 4.9 22.7 3.8 41.6 0.1 0.2 8.3 0.3    18.1 
20 625, 660 1.70 4.5 21 3.9 42 0.1 0.2 8.8 0.3    19.2 
21 660, 695 1.76 4.2 19.4 4 42.5 0.1 0.2 9.2 0.3    20.1 
22 695, 730 1.82 3.9 17.9 4.1 42.9 0.1 0.2 9.6 0.3    21 
23 730, 765 1.88 3.6 16.5 4.2 43.2 0.1 0.2 10 0.3    21.9 
24 > 765 1.93 3.4 15.5 4.2 43.5 0.1 0.2 10.3 0.3    22.5 
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To begin, the respective CT images were read in and their HU values were used to create 
an array containing the MCNP material number for each voxel location. Table 12 gives 
the HU range, density, and material composition in weight percent for each of the 24 
different materials used in MCNP. 
 
3.4.1 [18F]FDG Study 
 The first study was a [18F]FDG retro-orbital injection of 9997.4 kBq (270.2 µCi). 
The mouse was anesthetized using isoflurane for the for the retro-orbital injection, then 
allowed to wake up and become alert for approximately an hour before it was put to 
anesthetized again for subsequent imaging. The time of active wakefulness allowed the 
[18F]FDG to distribute throughout the different organs of the body and subsequent 
uptake in sites of high metabolic activity. The CT was set for a standard image with a 
scan time of approximately 3 min while the PET scan time was 60 min. 
  Figure 31 shows the micro-CT image acquired during this study. The micro-
PET/CT system saves the images files using the Analyze format, which were 
subsequently converted into DICOM format.  These files were then read by the python 
code creating a new array containing the material number for each voxel. This material 
array was further converted into a DICOM format for comparison purposes and is shown 
in Figure 32. 
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Figure 31. Slice image of the micro-CT for the animal study using [18F]FDG. 
 
 
 The CT and material images should appear similar with the exception that an HU 
range from -1000 to approximately 2000 is condensed to a range from 1 to 24 in the 
material image. 
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Figure 32. Slice image of the material values used in MCNP for the animal study using 
[18F]FDG. 
 
 
 After the material array is created, the PET images from the study are read in to 
create the source term for the MCNP input deck. The PET images are shown in Figure 
33 below. A large concentration can be seen in the eye socket where the injection 
occurred, bladder, kidney and brain. These are areas where higher radiation doses are 
expected in the MCNP output. 
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Figure 33. Slice image of the co-registered micro-PET and micro-CT for the animal 
study using [18F]FDG. 
 
 
 With all of these as input the program was executed and ran for 107 particles and 
the MCNP results in text format were converted again into DICOM format. Figure 34 
shows the voxel absorbed dose results co-registered with the original CT while Figure 35 
shows the relative error of the voxel dose. 
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Figure 34. Slice image of the co-registered dose and micro-CT for the animal study 
using [18F]FDG. 
 
 
 At first glance, Figure 34 looks as expected, with the lowest dose areas occurring 
outside of the animal in the air and highest dose areas occurring in the animal around the 
PET source locations. The scale is in units of Gy Bq-1 s-1, so the total dose to any voxel 
needs to be multiplied by the total number of disintegrations that are occurring in the 
body. 
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Figure 35. Slice image of the co-registered dose relative error and micro-CT for the 
animal study using [18F]FDG. 
 
 
 The relative error was calculated for the dose at each voxel. Most locations inside 
on the animal have a relative error below 0.10, while regions further away from the PET 
tracer location, like air, have higher relative uncertainties and the streaming effects of the 
created pair production photons can be seen. Continuing to run more particles will 
decrease the relative errors even further, but locations outside of the animal are not of 
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interest so as long as the relative doses inside the subject are below 20% it is not deemed 
necessary. 
 Rough segmentation was done on the images to determine mean absorbed dose 
values to potential organs of interest. Figure 36 shows the segmentation labels on top of 
the micro-CT slices as well as a 3D image of the regions in the bottom right corner. 
Table 13 gives the mean absorbed dose values for each region along with their standard 
deviation. 
 
 
Figure 36. Segmentation performed in ITK-SNAP provided mean values for the 
absorbed dose in different potential organs of interest for the animal study using 
[18F]FDG. Kidney is marked in red, Lung in green, Brain in blue, Heart in yellow, Bone 
– Femur in neon blue, Eye in pink, Bone – Spine in khaki, and Bladder in dark blue. 
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Table 13. Absorbed dose estimates of [18F]FDG for different target regions. The regions 
were delineated using the micro-CT images in ITK-SNAP. 
Tissue Absorbed Dose  (Gy Bq-1 s-1) Relative Error 
Kidney 3.86 ´ 10-12 0.065 
Lung 1.64 ´ 10-12 0.103 
Brain 2.19 ´ 10-12 0.086 
Heart 4.45 ´ 10-12 0.060 
Bone - Femur 5.88 ´ 10-13 0.161 
Eye 1.48 ´ 10-11 0.034 
Bone - Spine 7.98 ´ 10-13 0.141 
Bladder 4.02 ´ 10-11 0.026 
Whole Body 1.48 ´ 10-12 0.137 
 
 
 While the values in Table 13 come from a quick segmentation process they show 
some generally expected trends based on the distribution of the PET tracer used. For 
example, the eye and bladder, the two hottest locations on the PET image, have the 
highest absorbed dose values. The kidney, brain, and heart receive the moderate 
absorbed dose values and are also where our hotter spots were in Figure 33. Lower doses 
were seen in areas with less PET counts like the bones and lungs. 
 
3.4.2 NaF Study 
 The second study conducted was a tail vein injection of [18F]NaF with an activity 
of 5379.8 kBq (145.4 µCi). The CT was set for a standard image with a scan time of 
approximately 3 min while the PET scan time was 60 min. The CT images are presented 
in Figure 37 and are used to begin to create the MCNP input deck. 
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 The CT image is again taken and remapped from a range of -1000 to above 3000 
HU into twenty-four different material bins based on the HU value. The material images 
are shown in Figure 38 and are in good agreement with the CT images. The bone PET 
tracer serves as a minor contrast agent for the CT allowing the bones to be viewed more 
easily. Because of this, the tissue materials appear darker in this study than they did in 
the previous [18F]FDG study. 
 
 
 
Figure 37. Slice image of the micro-CT for the animal study using [18F]NaF. 
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Figure 38. Slice image of the material values used in MCNP for the animal study using 
[18F]NaF. 
 
 
 The PET images for this study are shown in Figure 39 below. Since the tracer 
[18F]NaF seeks out bone, the PET image is expected to highlight the bone regions, which 
it does. The spinal cord, ribs, and skull are all clearly visible in the PET image below 
and are areas where higher radiation doses are expected in the MCNP output. 
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Figure 39. Slice image of the co-registered micro-PET and micro-CT for the animal 
study using [18F]NaF. 
 
 
 With all of these as input, the program was run for 1.5 ´ 107 particles and the 
results were converted to the DICOM format. The relative error values were higher in 
this study due to the more localized source.  To counter this effect, more particles than 
the previous study were run to achieve relative error values on a similar scale. Figure 40 
shows the voxel dose results co-registered with the original CT while Figure 41 shows 
the relative error of the voxel dose. 
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Figure 40. Slice image of the co-registered dose and micro-CT for the animal study 
using [18F]NaF. 
 
 
 With a different PET tracer used, and therefore a different source starting 
position, a different dose map from the [18F]FDG study is expected and achieved. While 
the range of doses to each voxel remained similar between the two studies, the locations 
of the highest doses are quite different. In Figure 40, there is a much higher 
concentration of dose around the bone regions, which is expected since that is where 
more particles originate. Very low regions of dose, comparable to that of air, are also 
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seen in the body during this study which were not seen in the last study. This is again 
due to the source distribution where [18F]FDG will go to active metabolic sites 
throughout the body, while [18F]NaF focuses solely on the bones. 
 
 
 
Figure 41. Slice image of the co-registered dose relative error and micro-CT for the 
animal study using [18F]NaF. 
 
 
 The maximum error in the dose calculations is 1 and high errors are seen 
throughout the image. With the PET tracer being so localized to the bone many more 
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particles need to be run for this study to decrease the subject area’s relative error below 
the required levels. The maximum relative error currently inside the subject is below 
0.30. More computational time could be dedicated but was deemed unnecessary at this 
time. 
 
 
Figure 42. Segmentation performed in ITK-SNAP provided mean values for the 
absorbed dose in different potential organs of interest for the animal study using 
[18F]NaF. Kidney is marked in red, Lung in green, Brain in blue, Heart in yellow, Bone 
– Femur in neon blue, Eye in pink, Bone – Spine in khaki, and Bladder in dark blue. 
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 Rough segmentation was again performed on the images to determine mean 
absorbed dose values to potential organs of interest. Figure 42 shows the segmentation 
labels on top of the micro-CT slices as well as a 3D image of the regions in the bottom 
right corner. Table 14 gives the mean absorbed dose values for each region along with 
their standard deviation. 
 
Table 14. Absorbed dose estimates of [18F]NaF for different target regions. The regions 
were delineated using the micro-CT images ITK-SNAP. 
Tissue Absorbed Dose  (Gy Bq-1 s-1) 
STD 
(Gy Bq-1 s-1) 
Kidney 6.98 ´ 10-13 3.02 ´ 10-13 
Lung 4.70 ´ 10-13 2.62 ´ 10-13 
Brain 6.10 ´ 10-13 2.50 ´ 10-13 
Heart 2.10 ´ 10-13 1.23 ´ 10-13 
Bone - Femur 2.75 ´ 10-12 1.15 ´ 10-12 
Eye 1.39 ´ 10-12 4.78 ´ 10-13 
Bone - Spine 3.85 ´ 10-12 6.76 ´ 10-13 
Bladder 3.53 ´ 10-11 1.27 ´ 10-11 
 
 
 Comparing the [18F]FDG tracer absorbed dose values to the [18F]NaF absorbed 
dose values gives the expected results. There is a higher bone – spine and bone – femur 
dose since this tracer attaches to these regions with a higher affinity. The dose to the 
bladder remains similar in both studies because anything that is not up taken in the body 
will go to the bladder for excretion. The dose to all other areas of interest remain lower 
than the values in the precious study. The heart and kidneys both receive lower absorbed 
doses in this study than they did in the previous study. This shows the effects of 
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choosing the correct radio-labeled tracer for when conducting longitudinal studies. The 
absorbed doses to regions of interest change depending on that choice. 
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4 DISCUSSION 
 
4.1 Micro-CT  
 The goal of this work was to characterize a system that ideally needs to be 
invariant. This means it should be capable of providing, with high accuracy, the physical 
characteristic and resolution of the tissue types encountered in an animal model based on 
HU values obtained from CBCT. The present study showed that CBCT still has 
significant deficiencies when determining resolution, tissue composition and density of 
tissues. The HU values observed in CBCT were dependent on phantom geometry, 
generating significant variability for the same tissue type depending on phantom size and 
location, which presented in the form of “cupping” artifacts and large variations in HU 
values. Unlike clinical CT scanners, the reconstruction algorithm utilized by CBCT in 
the present study was not capable of correcting for beam hardening effects. The kVp 
values used by the Oxford Apogee x-ray unit are lower than those encountered in 
clinical CT x-ray units and the scanning method (axial versus conical) is quite distinct. 
Therefore, correction for “cupping” artifacts under CBCT remains a significant problem 
in image reconstruction. 
 Significant differences were observed between scanning phantoms (CISR versus 
QRM) which indicate that tissue quantitation by CBCT will require further research in 
addressing such differences in scanning geometry as the materials are standard for each 
phantom.  The resulting difference in HU values for each phantom study indicates that 
quantitation of tissues is still a significant metrological problem due to geometry and 
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consequent beam hardening effects. The corresponding tissue characterization becomes 
very uncertain depending on what calibration setting is used in the micro-CT. The 
resolution of the system and corresponding noise was also a significant issue in tissue 
characterization. The application of smoothing filters for tissue homogenization is not 
recommended as it removes the tissue interface between important organs and regions of 
the animal model, which in turn will make it more difficult to differentiate small organs 
and tissues, such as the lungs, trachea and esophagus when necessary. An example of 
this differentiation is shown in Figure 43.  
 
 
Figure 43. High resolution CBCT image for the chest of a mouse model showing a clear 
demarcation of the lungs, trachea and esophagus. The acquisition setting was 600 
projections. 
 
 
 The HU values resulting from CBCT studies using different phantom indicate 
that significant issues remain to be addressed when using CBCT. All the issues are 
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associated with high density objects, specifically bone structures. The correlation of 
measured HU versus density is quite linear from air through the dense bone region even 
though expected values show that there should be at least three different linear trends. 
There should be a linear trend between air and water, water and dense tissue types, and 
dense tissue types and bone. This is due to the calibration algorithm used in the machine 
which forces all measured values to appear within the same linear trend line. Much 
higher standard deviations or noise levels are seen in materials with increasing HU 
value. This is driven by CBCT “cupping” effects at high HU values. Moreover, tissue 
differentiation between breast and adipose is not possible due to the small difference in 
average HU value of each material and the large uncertainty that accompanies it. Muscle 
and liver also have a similar issue. These uncertainties are then translated into the tissue 
properties and uncertainty on dosimetry calculations using Monte Carlo transport 
methods. In metrological terms, the use of CBCT for the characterization of tissues in 
animal models of diseases is a substandard metrological modality.  
 The superficial and deep absorbed doses at 45 kVp at low and high current were 
also estimated. It was found that the absorbed dose delivered per standard scan are 
higher by a factor of 6 and 10 for the deep and superficial dose when compared with a 
nominal clinical CT scan. Higher superficial doses could lead to acute and late skin 
tissue effects, such erythema, squamous skin discharge, and inflammatory processes. 
These are all confounding factors that will interfere when studying the animal models of 
disease.  
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4.2 Positron Emission Tomography 
 The metrology of micro-PET in animal models of diseases was studied in terms 
of its resolution capacity based on MLEM reconstruction iterations and activity 
quantitation. The resolution of the micro-PET depended on the radioisotope in question. 
Fluorine-18 was the focus for this specific case; however, the same methods are required 
to assess the resolution for other radionuclides if deemed necessary. For example, 124I 
emits significant photons that will generate random coincidences in the PET detectors, 
which will decrease the resolution no matter how many iterations are used in the MLEM 
reconstruction algorithm. Figure 44 show a comparison of Derenzo phantom studies 
between 18F and 124I, which clearly show the loss of resolution by 124I using the same 
number of iterations. The nominal resolution at 10% obtained for 18F an 124I using the 
Derenzo phantom was 0.75 mm and 1.25 mm, respectively.  The lack of resolution is an 
intrinsic issue in the metrology of radionuclides in small animal models. The limiting 
factor continues to be the radionuclide photon spectrum quality (cleanliness), the PET 
detectors used, and the acceptance window of coincidence. Decreasing the acceptance 
window of coincidence, such as 40% to 20%, leads to a potential minimal increase in 
resolution and a significant increase in acquisition time, which may be detrimental to an 
animal under anesthesia. Therefore, the choice of radionuclide for molecular imaging 
needs to be carefully studied before embarking on a longitudinal study.  
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Figure 44. Derenzo phantom studies showing the difference in resolution between 18F 
(left – 10767 kBq, MLEM 120 iterations, voxel size 0.4 mm) and 124I (right – 2960 kBq, 
MLEM 120 iterations, voxel size 0.5 mm).  
 
 
 Once an image has been finalized, the next step is to convert the quantitative 
image given in counts per milliliter, into activity per milliliter. This process required the 
use of a calibration factor, Q, which was able to transform the image count data into 
activity data. It was observed that the calibration of the micro-PET for quantitative 
imaging was not simple. The plot of activity concentration versus mean counts showed 
an initial region of linearity, up to 80 kBq ml-1, followed by a region of saturation and 
under-response, up to 220 kBq ml-1, and ending in a region of supra-linearity above 220 
kBq ml-1. This study indicates that micro-PET systems are not always optimal systems. 
Quantification is necessary, as the data collected in the regions of saturation and supra-
linearity will probably be of no significance. Therefore, administered activities to the 
animal models at the time of imaging shall not be higher than 7400 kBq (200 µCi). 
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Higher administered activities at the time of imaging will results in an unstable micro-
PET system that will encounter significant dead times, an unreliable sinogram, and 
corresponding uncertainties or errors in reconstructed images. Therefore, the micro-PET 
system can only be utilized with precision and accuracy when the activity present in the 
system is below 7400 kBq (200 µCi).  
 
4.3 micro-CT and micro-PET Image Registration and Uncertainty 
 Co-registration of images is still a significant problem in preclinical molecular 
imaging. Lack of co-registration alignment will yield a poor or wrong image 
reconstruction, as the attenuation maps used from the CT for PET reconstruction will be 
incorrect. This in turn may assign regions or organs with an incorrect activity that will 
lead to an incorrect absorbed dose calculation. The cross-capillary method was found to 
be a cheap and efficient to determine fine locations points in each image which could be 
co-registered. This test can quickly and easily be performed to assure the user that the 
coordinate systems of each subsystem are correctly aligning. An error in co-registration 
would inherently decrease the resolution of the PET images even more, shifting the 
measured counts further away from their true location. The higher the accuracy achieved 
in co-registration the higher the accuracy of the absorbed dose map generated. 
 
4.4 Computational Assessment of Subject Absorbed Dose 
 The creation of a voxelized model in MCNP using a subjects CT to create the 
material and density maps and the PET to create the subjects source terms is fairly 
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simple. MCNP can now handle up to ~200+ million voxels. While the micro-PET/CT 
only contain ~2.8 million, clinical scans can be upwards of ~40 million. The more 
voxels used the more computational time required to achieve values with acceptable 
relative errors. Runs in the current study take two to five days depending on the number 
of computer cores available for processing. If energy deposition in each voxel was not 
required, but rather the deposition in certain materials, or organs, the computer time 
would be decreased but information about specific voxels would be lost. 
 With the calibration of the micro-CT machine the HU range was used to convert 
into material composition and density for use in MCNP. This requires translating a range 
of over 2000 HU values into 24 different material bins. With finer differences in tissue 
HU values and less system noise the material information used could be more defined 
leading to more accurate results. Creating finer bins with more density and composition 
accuracy would require a more in-depth study into the x-ray spectrum of the machine 
and its calibration factors for calculating HU values based off of the spectrums measured 
during the scans. 
 Segmentation was shown to be possible with the absorbed dose maps generated 
from the MCNP values. The whole subject or specific regions can be chosen to calculate 
specific absorbed doses. The only information required by the user is the injected 
activity in Bq and the amount of time doses should be calculated over in seconds. For 
example, the whole body mean absorbed dose for the study using [18F]FDG with an 
injected activity of 7400 kBq and an imaging time of one hour was 4.2 cGy. 
Incorporating the absorbed dose from the CT scan the total absorbed dose to the patient 
  94 
during the imaging study can be monitored. The ability to obtain these specific values 
could lead to more accurate studies and easier translation to the clinical level. 
  
4.5 Applications in Animal Models of Diseases 
 Depending on the type of disease and the treatment model different organs 
become the limiting factor. These limiting regions include the brain, heart, and bone 
marrow. The absorbed doses to these regions dictate the treatment doses that can be 
delivered to the target area. Absorbed doses to these organs and tissues must be tracked 
and accounted for when implementing longitudinal imaging studies focused on these 
areas so as to better distinguish effects from treatment versus effects from imaging. 
 
4.5.1 Radiation-Induced Cardiac Toxicity 
Radiation induced cardiac toxicity (RICT) or radiation-induced heart disease 
(RIHD) is a significant burden on patients that have undergone radiotherapy of the chest 
or other close by organs, such as those patients with breast cancer and Hodgkin’s 
lymphoma.  RIHD includes a wide spectrum of pathologies, such as coronary artery 
disease, myocardial dysfunction, valvular disorders, and pericardial disease.  The 
prevalence of RIHD varies among studies with between 20 – 40 % of patients mostly 
suffering from pericardial effusion [70, 71]. Damage to the myocardium is primarily 
caused by damage to the microvasculature due to capillary loss. The risk of developing 
RIHD is higher in young patients (< 20 y). Experimental animal studies have shown that 
radiation doses of  > 2 Gy are associated with increased expression of various 
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inflammatory cytokines and adhesion molecules in endothelial cells of both the 
microvasculature and large vessels [72]. However, under the paradigm of hormesis, it 
has been shown that whole-body doses of 0.1–0.6 Gy have been shown to inhibit 
leukocyte adhesion to endothelial cells in rats, and doses of 0.025–0.05 Gy exerted some 
protective effects on the development of atherosclerosis in ApoE-/- mice, particularly at 
low dose rates [72]. Animal models are being used to develop radio-protectants 
strategies against RIHD, which are capable of minimizing the acute and long term 
effects [73].  
In this study the total absorbed doses to the heart from combined micro-CT and 
micro-PET exposures were estimated at 0.3 Gy for a single imaging session using 
[18F]FDG. Over multiple imaging time points this could become a significant cumulative 
absorbed dose that becomes a confounding factor in cardiac toxicity studies. It would 
even be possible to go back to previous studies to determine specific organ absorbed 
dose values at a later date when symptoms or effects begin to present as long as images 
are stored with acquisition information (injected activity, scan time, etc.). The threshold 
for inducing cardiac toxicity depending on time of induction can be between 2 to 20 Gy 
[71].  
 
4.5.2 Radiation-Induced Brain Toxicity 
 During the treatment of head and neck tumors the limiting organ is the brain. In 
imaging, [18F]FDG goes to areas of high metabolic activity which includes the brain. For 
repeated longitudinal studies the absorbed doses to this region can become significant. 
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As seen from calculations, the dose to the brain during a single PET scan using 
[18F]FDG results in an absorbed dose of around 0.1 Gy. Monitoring of the absorbed dose 
value can lead to more accurate conclusion being drawn about the effects of the study 
target. 
 
4.5.3 Hematopoietic Toxicity 
 Within the bone marrow the effects of absorbed dose are relative to the amount 
of absorbed dose where even small doses can lead to measureable reductions in the 
proliferative capacity of bone marrow stem cells.  Early studies in dogs have shown that 
a dose rate of 0.075 Gy/day represents a threshold below which the blood-forming 
system retains its capacity for cell production for at least 1 year; however, at doses of     
> 0.075 Gy/day, nearly 60% of the irradiated dogs died from progressive aplastic anemia 
in less than 300 days.  In rats and mice exposed to long-term irradiation at doses of 0.01–
0.5 Gy/day (cumulative doses of 2–30 Gy) showed that the earliest and greatest 
depopulation occurred in the multipotent stem cell compartment [spleen colony-forming 
units (CFU-S)], which led to depletion of committed precursor cells and then of the 
functional cell pool.  Long-term exposure induces depletion of the bone marrow stem 
cell compartment and increases proliferative activity of these cells. Experiments in 
rodents show that increased proliferative activity of multipotent CFU-S occurs after 
exposure doses of 0.2–0.3 Gy; this leads to increased numbers of committed precursor 
cells and differentiated cells. Chronic exposures also stimulate proliferative activity in 
the committed precursor cells. Therefore, when molecular imaging studies are carried 
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out, consideration of doses to the bone marrow and spleen need to be well determine in 
order to assess any confounding factors that may be added to the research paradigm. The 
experimental evidence indicates that an acute threshold dose of 0.5 Gy be used for 
hematopoietic toxicity. The spleen and bone marrow can be carefully segmented out of a 
CT image and should appear as regions of higher activity using [18F]FDG in a PET scan. 
Unfortunately, the size of the structures makes monitoring these dose levels difficult 
without finer resolution in the imaging modalities. In our present [18F]FDG study the 
absorbed dose to the spine was estimated at 4.4 cGy and 3 cGy to the femur. If multiple 
studies are carried out, then the total cumulative dose to the bone marrow will be 
significant and comparable to the doses where hematological toxicity may be of concern.  
 
4.5.4 Animal Models of Regenerative Medicine 
Cell-based regenerative medicine therapies (RMTs) and their translation to 
clinical application are a major focus of research and play a key role in future clinical 
practice.  Cell-based RMTs include various cell types, such as stem cells, stromal cells, 
and macrophages and have the potential to treat multiple diseases. Many RMTs have 
shown great promise in preclinical studies for various diseases, including kidney and 
liver diseases and myocardial infarction; however, translation into the clinic has been 
limited. The slow translation from bench-to-bedside is due to the lack of convincing 
animal models and reproducible data on the safety, efficacy and mode of action of 
RMTs.  
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Relevant rodent animal models are needed to gain an understanding of both the 
efficacy and the safety of cell-based RMTs. Current methods generally rely on ex vivo 
histological analysis of tissues post-mortem. This approach requires many animals to be 
sacrificed at multiple time points in order to gain a comprehensive insight into in vivo 
processes. Importantly, it does not allow researchers to monitor individual animals over 
the course of their treatment. This need is being addressed by using molecular imaging 
methods that monitor the longitudinally response of every animal thus minimizing 
animal use and acquiring higher fidelity morphological and physiological data.  
There are multiple animal models of regenerative medicine depending on the 
target organ to be considered. The use of micro-PET/CT provides high sensitivity 
morphological and physiological data, which is an advantage for tracking anatomical 
localization of stem cells and PET imaging and using reporter genes permits long-term 
studies. By directly labeling cells with PET probes, such as 18F, 64Cu, or 124I it is possible 
to monitor the fate of these labeled cells throughout the body, including their 
proliferation. Because of the high sensitivity of the micro-PET/CT, it is possible to 
detect as few as 10 labeled cells with a minimum activity 0.1 kBq. However, the 
absorbed doses delivered by the micro-CT are of great significance and may induce 
changes in multiple organs and tissues by inducing radiobiological changes in the 
microenvironment and stem cells.  Stem cells have been labeled with PET probes to 
assess their fate in the hippocampus for brain function, in the kidneys, lungs and bone 
marrow [74]. 
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4.6 Advantages and Limitations of micro-CT versus micro-MRI 
 Most of the issues and disadvantages discussed with micro-CT above can be 
resolved by the use of a micro-MRI. The move from micro-CT to micro-MRI imaging is 
currently being commercialized by one commercial company, Bruker Biospin, Inc. In 
pre-clinical imaging studies, scanning times required for MRI imaging are similar to 
those of micro-PET, which are around 60 min; thus, the simultaneous acquisition of the 
PET and MRI will be similar. A list of the advantages of both modality types is given in 
Table 15. The benefits of MRI are higher tissue characterization and differentiation, 
inclusion of functional imaging and spectroscopy, use of radioactive and non-radioactive 
binary probes, and no radiation exposure from x-rays. Clearly, the ability to discriminate 
between tissues greatly increase the accuracy of calculated absorbed doses. However, the 
long scan times produce some blurring on active organs and tissues regions of the body, 
such as the lungs and heart. The MRI signal will be the average value at the target 
location over the scanning time instead of the more accurate representation of the faster 
CT imaging modality, which would incorporate less motion. As an example, Figure 45 
shows the acquired micro-PET/MRI image for comparison to the micro-PET/CT images 
displayed in the present work. MRI images provide a significant advantage for tissue 
segmentation when compared to CT images.  
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Table 15. Advantages of hybrid PET/MRI versus PET/CT in small animal imaging. 
Attribute Micro-PET/MRI advantages Micro-PET/CT advantages 
Lesion detection Improved lesion detection (i.e. 
colorectal, lung, osteosarcoma, and 
bony metastases)  
No advantage 
Lesion margins Better delineation of tumors and 
classification  
Improved delineation of 
lesion margins within lung 
parenchyma 
Lesion alignment Better alignment of simultaneously 
acquired PET/MRI data when 
compared with PET/CT 
No advantage 
Quantitative 
analysis 
Improved quantification by MRI-
based motion correction without 
additional radiation 
Current standard based on 
density seen on CT 
Scanning time No advantage Micro-PET/CT scanning 
protocols are currently 
faster 
Radiation 
exposure 
No CT reduces radiation exposure 
to animals  
No advantage 
Animal 
accessibility 
Simultaneous acquisition (PET 
insert)  
In line  
Multi-parametric 
analysis  
Expanded capabilities such as DWI, 
perfusion MRI, fMRI, MR 
spectroscopy, and use of binary or 
multiple MRI and PET probes 
No advantage 
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Figure 45. Micro-PET/MR imaging of a tumor-baring mouse injected with 100 MBq of [18F]FDG using MR attenuation 
correction mapping. Acquisition time of 600 sec.  
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5 CONCLUSIONS 
 
5.1 General Conclusions 
In this work, we have established the necessary tools for creating a quantitated 
system encompassing not only the imaging units of the micro-PET/CT but also the 
quantitation of activity distribution and dosimetry of the imaged animal as well. To 
begin the subsystems were quantified for their response to changes in the imaging 
object. For the micro-CT this included understanding the relationship between tissue 
type, composition, and density and how it related to the values provided in the CT 
images after reconstruction. The absorbed doses for different micro-CT scanning 
methods were also measured so as to gain the ability to track subject dose reviewed from 
the whole imaging study, CT and PET combined. 
 The micro-PET system was quantified next to gain an understanding of the 
resolution of the subsystem and explore the capabilities and limitations of the machine 
when applying radiolabeled tracers. Once this characterization was determined, the 
system was evaluated for its count response versus activity over time. It was observed 
that the micro-PET system does not respond linearly as function of activity 
concentration. Regions of linearity, supra-linearity, and saturation were all observed. 
The response allowed for the counts in a reconstructed PET image to be converted to an 
activity concentration, but only as long as the concentration remained in the linear region 
of the plot. This region of linearity limited the total injected activity at the time of 
imaging to be no more than 7400 kBq (200 µCi). 
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 With each subsystem characterized separately, the image co-registration of the 
modalities was then measured to verify that the coordinate systems of each system were 
correctly aligned within 1 mm. A cross-capillary method was used to determine the 
offset in the x, y, and z directions which were later used as correction factors when 
aligning the images during co-registration. This ensures a correct PET reconstruction 
with the correct attenuation map, as well as the attribution of the correct amount of 
activity concentration to the true voxel location in the CT image. 
 Once the whole systems response to imaged subject was quantified the data was 
used to generate an input deck for MCNP6 to calculate the dose received by each voxel 
from the radiolabeled tracer injected during the imaging study. Two different tracers 
were studied, and the results showed the expected differences between the two. The 
[18F]FDG study, and delivered high absorbed doses to the kidney’s, heart, and brain. On 
the other hand, the [18F]NaF study delivered high absorbed doses to bone surfaces. With 
the generation of animal specific absorbed dose maps, investigators can segment tissues 
or a region of interest for further dosimetry analysis. This can allow the dose to a 
particular organ or tissue to be tracked across an entire longitudinal study of the animal 
and be included in the analysis on the effectiveness of treatment options tested. In the 
present study, the radionuclide selected was 18F; however, it is possible to carry out the 
same procedures for other radionuclides, such as 124I as long as the source distribution 
tracer is deemed to be the same distribution the radionuclide of interested in known to 
have.  
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5.2 Future Work 
 The first step in continuing this work is to more fully understand the micro-CT 
detector response to materials. If the material information can be known with greater 
accuracy the creation of materials in MCNP becomes more accurate as well as the 
results it produces. The implementation of this process on a different pre-clinical 
machine and the ability to measure the same subject and compare results would further 
corroborate the claims made in this research. Finally, the implementation of this work in 
longitudinal studies to determine if dose thresholds for specific radiation effects are 
reached would show the necessity for the ability to track organ specific absorbed dose 
values across multiple time points in a longitudinal study. 
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